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ABSTRACT 
The objective of this project was to develop advanced nanocarriers such as 
nanographene and graphene quantum dots against atherosclerosis. Mannosylated-reduced 
graphene oxide (Man-rGO) was developed as a targeted nanocarrier and its therapeutic 
efficacy was evaluated. Near-infrared (NIR) irradiation increased the temperature of 
Man-rGO solution to approximately 45 °C. Man-rGOs mainly accumulated at the 
subcellular level of M2-phenotype macrophages (Raw264.7 induced by interleukin-4 (IL-
4)). The cell viability of macrophages significantly decreased upon exposure to Man-rGO 
irradiated with NIR, but no changes were observed from that of mast cells (for mast cells 
(RBL-2H3), 98.3±0.3%; for macrophages, 67.8±1.3%, p<0.01). The enhanced 
photothermal ablation activity of Man-rGO triggered by NIR laser irradiation was 
mediated through their targetability toward overexpressed mannose receptor (CD206), a 
marker of M2-phenotype macrophage.  
Thiolated-graphene quantum dots (SH-GQDs) were explored as a theranostic 
nanocarrier against atherosclerosis. SH-GQDs with high quantum yields can be utilized 
to label single-cell biophysics in the absence of any extra fluorescent dyes. SH-GQDs 
treatment for 24 hr was effective to induce oxidized-low density lipoprotein (oxLDL) 
efflux as compared to the media control (Media: 72.4±2.4% and SH-GQDs: 39.2±2.2% 
	 iv 
of oxLDL present in macrophages). There was a significant difference in the efflux 
amount of oxLDL incubated with SH-GQDs between two treatment periods (3 hr: 
73.9±1.5% and 24 hr: 39.2±2.2%). The expressions of ABCA1 in macrophages treated 
with oxLDL decreased (oxLDL: 79.2±1.7%), whereas the level of ABCA1 expression 
increased as cells were incubated with SH-GQDs in a presence of oxLDL (SH-GQDs: 
101.5±3.1%). Disrupted adherence junctions of human umbilical cord-derived vascular 
endothelial cells (hUVECs) after oxLDL treatment were observed (oxLDL: 67.2±2.2 Ω-
cm2 for 24 hr). SH-GQDs (10 µg/ml) showed an improvement in transepithelial electrical 
resistance (TEER) (SH-GQDs: 114.6±8.5 Ω-cm2 for 24 hr), indicating that adherence 
junctions were protected by SH-GQD treatment. SH-GQD treatment on in vivo zebrafish 
larvae showed a protective role of SH-GQDs against oxidative stress induced by H2O2. In 
addition, as the concentration of SH-GQDs increased, the fluorescence intensities 
lowered, and were close to negative control. The increased reactive oxygen species 
(ROS) levels caused by oxidative stress were mostly relieved by the addition of SH-
GQDs.  
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CHAPTER 1 
  INTRODUCTION 
 
1.1. Overview 
Coronary artery diseases (CAD) induced by genetic factors and dietary habits 
have remained a potentially fatal disease (Halon et al. 2004; Tanous et al. 2006). CAD is 
the No. 1 killer in the United States of America, affecting more than 13 million 
Americans (Mozaffarian et al. 2015). Among them, atherosclerosis is the primary source 
of heart disease, leading to serious pathological symptoms, such as myocardial infarction 
and angina (Roger et al. 2012; Joshi et al. 2015). Atheroma composed of depositing 
cholesterol on the endothelial surface could be ruptured, as the accumulative amount of 
cholesterol increases (Stary 2000). Eventually, coronary artery will be blocked by platelet 
adhesion due to the collapse of atheroma mediated through anti-inflammatory response. 
Endovascular stents have been extensively emphasized in the field of 
interventional cardiology and been regarded as the most important breakthrough in the 
treatment of numerous vascular diseases (Bonaventura et al. 2012; Liistro et al. 2012; 
Roselli et al. 2015). There are various types of endovascular stents, which have been 
introduced to the field including bare-metal stent (BMS), polymeric-coated stent, and 
drug-eluted stent (DES) (Kabir, Selvarajah, and Seifalian 2011; Kobayashi et al. 2016). 
Despite of promising clinical outcome, recent studies have been reported that DES can 
cause late stent thrombosis and result in long-term failure, especially after stenting 
complex lesions (Teirstein 2010). This was because the release of anti-proliferative 
agents such as Sirolimus or Paclitaxel hindered not only smooth muscle cells (SMCs) 
	 2 
migration, but also re-endothelialization rate on the substrate. In addition, since the stent 
surface was very limited, it is very difficult to deliver the effective amount of therapeutics 
in long-term treatment (Abizaid et al. 2007).  
Macrophage accumulation within the vascular wall plays a critical role in the 
development of atherosclerosis (Medbury et al. 2013; Chinetti-Gbaguidi, Colin, and 
Staels 2015). Macrophages own distinctive flexibility of response to environmental 
signals (Han et al. 2013; Garris and Pittet 2013). Foam cells derived from macrophage 
necrosis are a known indicator of the initial stage of atherosclerosis (Han et al. 2014; Oh 
and Lee 2013b). The uptake of modified lipoproteins including oxidized low density 
lipoprotein (oxLDL) is an integral step for foam cell formation. It has been reported that 
macrophages upon exposure to oxidative lipids produced an apoptosis inhibitor of 
macrophages (AIM or Spα/Api6) (Arai et al. 2005). It was also suggested that AIM 
production promoted macrophage survival within atherosclerotic plaque and an inhibition 
of AIM via genetic knockout model AIM-/-LDLR-/- lowered progression of plaque 
development. Thus, to promote macrophage apoptosis will be a promising approach to 
prevent early lesion development.  
Reactive oxygen species (ROS) is believed to be the detrimental cause of 
numerous diseases, such as neurodegenerative disease, diabetes and cardiovascular 
disease (Spector 2000; Brieger et al. 2012). Particularly, it was reported that the 
accumulation of ROS at the subcellular level of endothelial cells disrupted redox balance 
of endothelial cells, which ultimately inducing apoptosis of thin layer of atheroma by 
which thrombosis occur (Swindle and Metcalfe 2007). Moreover, the uptake of oxLDL 
by macrophages via macrophage scavenger receptor (MSR-A or CD204) generates 
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overproduction of reactive oxygen species (ROS) at the subcellular level and causes a 
down-regulation of ATP-binding cassette transporter (ABCA1). The uptaken oxLDL 
ultimately leads to the formation of foam cells, resulting in plaque development and 
chronic inflammation (Rader and Pure 2005; Sun et al. 2015). Although the popular 
pharmacologic agents including statins have been widely used to systemically inhibit the 
synthesis of cholesterol, various side effects as well as the lack of therapeutic efficacy 
and diagnostic property may pose as a main obstacle for its clinical application. 
An advanced therapy that can resolve the cause of atherosclerotic plaque is 
integral in the treatment of atherosclerosis. The majority of atherosclerosis research in the 
field has been aimed to develop new type of endovascular stent with less 
immunogenicity. Nanomedicines designed for competitive binding to MSR-A can switch 
lipid-scavenging macrophages to anti-atherogenic phenotypes, thus alleviating 
progression of atherosclerotic plaque (Lewis et al. 2015). Therefore, new bioactive 
nanocarriers that regulate the uptake of oxLDL via interaction with MSR-A can serve as 
an efficient strategy to prevent the development of atherosclerotic plaque.   
In this dissertation, we have attempted to develop nanographene platforms for 
photothermal ablation of atherosclerotic macrophages and diagnostic property. The 
structural properties of nanographene platforms and carriers were characterized. We have 
identified key parameters in determining drug-carrier compatibility and miscibility using 
in vitro and in vivo optical imaging studies. We have applied nanographene carriers to 
lipid-laden macrophages to stimulate oxLDL efflux via up-regulation of ABCA1. The 
pharmacological efficacy of nanographene carriers was evaluated on the cell lines and 
zebrafish model and the potential cardiotoxicity was examined. 
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1.2. Statement of the Problems 
Atherosclerotic occlusion is one of the main contributors to myocardial infarction 
and angina. Although several efforts have been made to cure the coronary artery disease 
(CAD), the satisfactory CAD treatment option is still not available. Only less than 22% of 
stents used for CAD remains without complications after 3 years of placement. The 
engulfment of particulates by macrophages is a critical problem in therapeutic treatment 
as well as molecular imaging. Nanocarriers acted as an image-guided carrier against 
plaque lesion will be an ideal option for the treatment of atherosclerotic occlusion.  
Macrophages are considered to play a crucial role in the atherosclerotic plaque. 
The accumulation of oxLDL within macrophages is a hallmark of foam cell formation, 
resulting in plaque development. Early macrophage apoptosis appears to have an ultimate 
beneficial effect on atherosclerosis, which is largely due to the ability of phagocytes to 
efficiently clear the dead macrophages in the initial lesion. However, there is no effective 
means to specifically induce macrophage apoptosis.  
Nanocarriers designed for specific binding to CD204 are critical in the treatment of 
atherosclerosis. The competitive binding of nanocarriers to CD204 will alleviate lipid-
laden macrophages, thus preventing progression of atherosclerotic plaque. For this 
purpose, we will deplete macrophages by employing nanographene based advanced 
system that efficiently eliminates the atherosclerotic plaque via photothermal ablation 
triggered by near-infrared laser. In addition, graphene quantum dots functionalized with 
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thiol as an anti-oxidant will be proposed to control the oxLDL uptake via CD204 and to 
up-regulate ABCA1 expression, thus lowering lipid accumulation at the subcellular level 
of macrophages.  
 
1.3. Objectives 
The objectives of this dissertation are: 
1. To develop and characterize the targeted-nanographene carrier (Mannosylated-
reduced graphene oxides) for photothermal ablation of M2-phenotype macrophages.  
2. To develop and characterize the thiolated-graphene quantum dots as a theranostic 
nanocarrier (therapy with diagnostic).  
3. To study in vivo ROS scavenging efficacy and potential toxicity of functionalized-
nanographene formulations on the mouse macrophage cells and zebrafish model.  
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1. Anatomy and Physiology of Atherosclerotic Plaque 
Atherosclerosis is no longer considered as a simple fat buildup that lead to 
progressive narrowing of the arterial wall, but is now considered as an active cellular 
process (Agarwal et al. 2012). A formation of atherosclerotic plaques generally causes 
severe pathological symptoms including luminal narrowing and vulnerable plaque 
rupture which are stimulated by both macrophage-derived metalloproteinase and cyclic 
mechanical stress of the luminal blood stream (Rader and Pure 2005). These symptoms 
can eventually lead to occlusive thrombosis, the underlying cause of the majority of 
sudden cardiac death. 
 
Anatomy of Artery Wall 
Arterial wall consists of three important layers: the tunica intima, tunica media 
and tunica adventitia (Figure 1) (Kohn, Lampi, and Reinhart-King 2015). The innermost 
layer or tunica intima contains the endothelium, which directly contact with blood flow 
and perfusion pressure.  In addition, the endothelium of the tunica intima is responsible 
for preventing the blood from clotting. The tunica media is primarily smooth muscle and 
is the middle layer of the artery. The tunica media maintain the vessel contractility and 
allows for the flow of blood. The tough outermost layer is the tunica adventitia. This 
connective tissue layer consists of varying amounts of elastic and collagenous fibers.  
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Pathophysiology of Atherosclerotic Plaque 
Various risk factors including dyslipidemia, tobacco smoking, hypertension, 
diabetes mellitus, obesity and lack of physical activity accelerate irreversible damage to 
the endothelium lining, resulting in high inflammatory cell infiltration (Insull 2009).  
Abnormal levels of LDL, oxLDL and high glucose in blood considerably 
contribute to pathological intimal thickening (PIT) as the earliest feature of progressive 
atherosclerosis (Figure 2) (Otsuka et al. 2015). Inflammatory cytokines and oxygen 
radicals exerted at the intima layer of the artery convert LDL to oxLDL that initiate the 
inflammation. The infiltration of monocytes is a distinctive characteristic of progressive 
atherosclerosis. Local secretion of cytokines and ROS will trigger monocytes 
differentiation into macrophages. Macrophages engulf lipid crystals such as LDL or 
oxLDL, causing immunological changes. The inflammation accelerates extracellular lipid 
accumulation, leading to the progression and destabilization of fibrous caps. 
Macrophage differentiation and apoptotic bodies in plaque lesion are greatly 
associated with the progression of coronary plaques from PIT to late fibroatheroma. 
During the plaque progression, it was found that macrophage population, apoptotic 
bodies and defective clearance by macrophages increased. Plaque development and 
progression are related to macrophages with lesional compilations including lipid 
deposition, proteoglycan production and hyaluronan accumulation, eventually resulting in 
narrowed artery formation.  
Blood flow through narrowed artery generates hemodynamic force and stress to 
endothelium, leading to atheroma disruption.  As atheroma composed of depositing 
cholesterol on the endothelial surface is ruptured, lipid crystal and collagen matrix come 
	 8 
in contact with blood. Eventually, coronary artery will be blocked by platelet adhesion 
due to the collapse of atheroma mediated through anti-inflammatory response. 
Biomechanical response has led to thrombosis formation, eventually leading to plaque 
calcification and blocking blood flow. Partial or complete blockage of perfusive flow 
irreversibly damages to cardiomyocytes, causing acute myocardial infarction or angina.  	
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Figure 1. Composite structure of the artery. Adopted from (Kohn, Lampi, and Reinhart-
King 2015).  
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Figure 2. Histology analysis of pathologic intimal thickening (PIT) with or without 
macrophages, early fibroatheroma (EFA) and late fibroatheroma (LFA). The left two 
columns demonstrate low and high power images of sections stained with Movat 
pentachrome. The right three columns display high power images of 
immunohistochemical stains for macrophages, T-lymphocytes, and vaso vasorum. 
Adopted from (Otsuka et al. 2015). Reprinted with permission from Atheroslcerosis.  
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2.2. Significance of Macrophage in Atherosclerotic Plaque 
Monocytes are intensely mobile cells that regulate the innate immune system 
(Figure 3) (Moore, Sheedy, and Fisher 2013). Macrophages differentiated from infiltrated 
monocytes can be monitored in the intimal and medial layers in blood vessels. 
Macrophages scavenge cellular debris and capture pathogens. Macrophages are central to 
vascular inflammation and play an essential role in onset and progress of atherosclerosis 
(Yan and Hansson 2007). Pathological processes including luminal narrowing, 
macrophage-derived metalloproteinase and cyclic mechanical stress of the luminal blood 
stream can eventually lead to occlusive thrombosis, the underlying cause of sudden 
cardiac death (Rader and Pure 2005). 
 
Role for Macrophage Apoptosis in Atherosclerosis Development  
The uptake of oxLDL in macrophages is an initial step for lipid-laden macrophage 
formation. Macrophages possess distinguished flexibility of response to modified 
lipoproteins.  Macrophage in response to oxLDL induces a cell signal such as apoptosis 
inhibitor gene expression (AIM or Spα/Api6) (Arai et al. 2005). It has been reported that 
AIM signal prevented lipid-laden macrophages from apoptosis within atherosclerotic 
plaque. AIM inhibition study using AIM-/-LDLR-/- model demonstrated substantial 
decrease in plaque development, indicating that macrophage survival against 
environmental signals such as LDL or oxLDL can be facilitated by AIM expression. 
Increasing macrophage apoptosis by genetic modification or external stimuli will be a 
promising strategy to prevent early lesion development.  
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A Subset of Macrophages in Atherosclerotic Plaque Lesion 
M1-phenotypic macrophages: The recruited-monocyte activated by external stimuli (i.e. 
intercellular uptake of oxLDL) caused their polarization to M1 macrophage (Moore and 
Tabas 2011), which was implicated in the early phases of atherosclerosis (Libby, Ridker, 
and Hansson 2011). M1 macrophages released pro-inflammatory cytokines and reactive 
oxygen or nitrogen species that would aggravate oxidative stress in plaque lesion (Moore, 
Sheedy, and Fisher 2013).  
M2-phenotypic macrophages: M2 macrophages (also known as alternatively activated 
macrophages), on the other hand, are immunosuppressive and resolve plaque 
inflammation (Laskin 2009). As a novel strategy would be to reduce the inflammatory 
state of plaque macrophages, re-polarizing macrophages to be transformed into M2 
phenotype might be particularly effective (Moore, Sheedy, and Fisher 2013). Because M2 
macrophages secrete anti-inflammatory factors and promote tissue remodeling through 
the clearance of dying cells and debris, the relevant polarizer inducing M2 phenotypes 
can be emerged as an alternative route for an atherosclerosis treatment.  
However, M2-phenotype macrophages will accelerate the progression of 
atherosclerosis. A subset of macrophages (M2) in lesions with the atherosclerotic plaque 
overexpresses mannose receptors (MRs or CD206) (Figure 4) (Tahara et al. 2014). 
Previous studies showed that the expression of MR-bearing M2 macrophages were 
enhanced in unstable plaques, indicating that the overexpression of MRs in high-risk 
plaques could provide an additional opportunity for targeted delivery (Tahara et al. 2014).  
The expression of several scavenger receptors, such as SR-A1 (CD204) and 
CD163, in M2-phenotypic macrophages increased. The increased expression of SR-A1 
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and CD163 contributes to the prototypical M2 functions including apoptotic cell 
clearance, sequestration of the inflammatory cytokine and hemoglobin–haptoglobin 
complexes at sites of tissue damage and the subsequent production of anti-inflammatory 
cytokines. However, enhanced expression of SR-A1 on M2 macrophages can stimulate 
the uptake of LDL or oxLDL via scavenger receptors. LDL or oxLDL can be 
accumulated at the subcellular level of macrophages, causing the accelerated formation of 
foam cells (Figure 5) (Canton, Neculai, and Grinstein 2013).  
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Figure 3. Monocyte recruitment through endothelial cells. Monocytes differentiation into 
macrophages. Lipid-laden macrophages eventually form foam cells releasing retention 
molecules, cytokines and chemokines.  
Adopted from (Moore, Sheedy, and Fisher 2013). Reprinted with permission from Nature 
Review Immunology.  
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Figure 4. MR-bearing macrophages in stable and high-risk atherosclerotic plaques. (a) 
and (b) Top, photomicrographs of adjacent sections of stable coronary atherosclerotic 
plaque stained for CD68 (macrophages), CD163 (M2 macrophages) or CD206 (MR-
bearing macrohages). Bottom, high-power views of the plaque shoulder region 
corresponding to the black box in the top left photomicrograph. LP, lipid pool; NC, 
necrotic core; PIT, pathologic intimal thickening. 
Adopted from (Tahara et al. 2014). Reprinted with permission from Nature Medicine.  
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Figure 5. Scavenger receptors contribute to the functional phenotype of polarized 
macrophages.  
Adopted from (Canton, Neculai, and Grinstein 2013). Reprinted with permission from 
Nature Reviews Immunology.  
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Macrophage-Autophagy (MA) Dysfunction in Atherosclerotic Plaque 
Autophagy plays a critical role in turning over organelles and proteins to maintain 
the cellular homeostasis (Choi, Ryter, and Levine 2013) at the infection site (Baruch et al. 
2013). As autophagy becomes activated by external stresses (i.e. reactive oxygen 
species), it induces SMCs and ECs proliferation by eradicating intracellular debris 
(Ouimet et al. 2011). However, autophagy under excessive stimulation can cause necrotic 
death of both SMCs and ECs, resulting in thinning fibrous cap and weakening the 
stability of plaque (Schrijvers, De Meyer, and Martinet 2011).  
MA has contributed the disruption of vascular pathology, resulting in chronic 
atherosclerosis (Martinet et al. 2013). Macrophage accumulated the cholesterol as a form 
of lipid droplets by uptake of oxLDL, leading to the formation of foam cells (Maiuri, et 
al. 2013). With excessive oxidative stress from oxLDL, macrophage ultimately rupture 
and accumulate additional lipids into arterial intima. The high level of atherosclerosis-
relevant factors triggered the stress reaction of endoplasmic reticulum (ER) in 
macrophage, causing the activation of ER apoptotic pathways (Virmani et al. 2002). The 
necrotic death of macrophage associated with defective phagocytic clearance of the 
apoptotic cells destabilized plaque, which orchestrates an acute atherothrombotic event 
(Liao et al. 2012; Tabas 2010). 
The functional relationships between MA and defective efferocytosis have been 
studied (Liao et al. 2012). As MA was inhibited by silencing autophagy mediators 
(Autophagy-related protein-5, ATG5), the increases in apoptosis and oxidative stress 
mediated from NADH oxidase were observed. During the observations, the necrotic cells 
(apoptotic debris) were not recognizable through efferocytosis. in vivo data using 
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macrophage ATG5-null mice in fat-fed LDLR-/- suggest that plaque destabilization 
associated with the necrotic disruption of foam cells and worse in lesional efferocytosis 
were highly correlated with an autophagy expression. In addition, ATG5-null mice co-
incubated with lipid crystals showed remarkably induction of inflammasomes, resulting 
in deficient stability of plaque in part of hyperactivation of inflammasomes.  
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2.3. Current Treatment Strategies against Atherosclerosis 
Anti-Inflammatory Therapy using Monoclonal Antibody (mAb) 
The inflammation associated with leukocyte subpopulations and secretion of 
cytokines is recognized as to play a pivotal role in promoting atherosclerotic plaque 
growth and in subsequently destabilizing the atheroma (Mor et al. 2013; Sun et al. 2007; 
Kodali et al. 2006). Since the chronic inflammation obviously involves with the rupture 
of plaque, the modulation of the immune response is now viewed as a potential avenue of 
therapy (Hansson and Libby 2006; Galkina and Ley 2009; Kuiper et al. 2007; Lacek et al. 
2012). The utilization of mAb has been widely established in a wide range of conditions 
such as cancers, the rejection of implanted transplants, and infectious disease (Scott, 
Wolchok, and Old 2012; Topalian et al. 2012; Ansari et al. 2013). These biotherapeutics 
have a higher potency than the conventional small-molecule therapeutics as the 
specificity at the target site and less dosing frequency could be enhanced (Casi and Neri 
2012; Choi et al. 2013).  
In general, mAbs are well tolerated and have some advantages such as the 
specificity for their target, no interaction with cytochrome p450 and other transport 
proteins in the body. This caused reduced potential for drug-drug interactions (Catapano 
and Papadopoulos 2013). Circumstantial evidence demonstrates that eotaxin-2/CCL24 
(EO-2) may play an essential role in the atherosclerotic progression (Salcedo et al. 2001). 
In a subsequent study, the high level of induction of EO-2 circulating is associated with 
the presence of coronary artery disease such as atherosclerosis (Emanuele et al. 2006). In 
a recent study, it has been reported that blocking the EO-2 pathway by a newly-
developed monoclonal antibody, D8 may represent the inhibition of fatty streak 
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formation and reduce the plaque size as employed to the ApoE-/- mouse model (Mor et al. 
2013). Likewise, various receptors causing an initiation of plaque formation would be 
recognized as a therapeutic targeting. It has been recently reported that BAFFR (B cell 
activation factor of the TNF family)-Receptor might be a potential target to attenuate the 
atherosclerotic plaque (Kyaw et al. 2013). BAFF is widely expressed by immune cells, 
primarily macrophages (Brink 2006). The induction B-cells by the interaction between 
BAFF and these receptors (BAFFR) could exacerbate the plaque instability. Anti-BAFFR 
monoclonal antibody has been developed and it ameliorated the progression of 
established atherosclerosis (Kyaw et al. 2013). This mAbs were targeting B2 cells-
depletion in atherosclerosis lesion, resulting in an attenuation of pathological progression.  
However, the cytotoxic impacts of immune-modulation therapy on unintended 
tissue or target molecules are frequently found (Hansel et al. 2010). The toxicity related 
to mAbs can be dependent on the activity of the mAbs due to the ramification of 
interaction with target molecules (i.e. protein or receptor) or non-specific targeting on 
target tissue (i.e. off-target) (Gorovits and Krinos-Fiorotti 2013). In addition, the major 
barrier is associated with a delivery route. The advanced knowledge for an appropriate 
delivery carrier or route of administration should be cumulated. 
 
Site-Specific Targeting Antibody Mediated by Pro-Antibody Design 
As the antibody-therapeutics are bound in normal tissue, the patients have 
detrimental impacts including the increase in apoptotic pathway, on-target toxicities 
during the treatment, and reduced patient compliance (Hebar, Valent, and Selzer 2013). 
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Given these problems, several distinct strategies have been reported to enhance the 
selectivity of antibody therapeutics (Bordon 2013).  
Locally activated proteolytic enzymes are highly expressed at various 
pathological lesions such as neurodegenerative diseases, oncological diseases, and 
cardiovascular diseases (Huntley 2012; X. W. Cheng et al. 2012; Singh et al. 2012). 
Consequently, site-specific proteases are exploited as a targeting moiety (Chien et al. 
2013; Dufour and Overall 2013). In atherosclerotic plaque, it has been well-known that 
latent-matrix metalloproteases family (i.e., MMP-1, 8 and 9) have been activated by 
exocytic components such as reactive oxygen species and inflammatory cytokines 
(Ketelhuth and Back 2011). The activated-MMP family could destabilize the plaque as 
the type-1 collagen matrix in the fibrous cap is degraded (Peeters et al. 2009). It has been 
recently reported that anti-VCAM-1 conjugated pro-antibody containing protease 
cleavable substrates was designed to render a specific binding affinity upon protease in 
atherosclerotic tissue (Erster et al. 2012). The subsequent in vivo study demonstrated that 
the pro-antibody was efficiently activated by activated proteases in aorta tissue extracts 
from ApoE-/-. No increase in the activation of pro-antibody was found as treated by the 
extracts from normal mice. It indicated that the proteases (activation of MMP family) 
could be exploited to site specifically target atherosclerotic lesion in vivo.  
Newly developed microvessel in the plaque is a feature of angiogenesis induced 
by hypoxic condition (Marsch, Sluimer, and Daemen 2013; Parathath et al. 2011). The 
extradomain B of the extracellular matrix glycoprotein fibronectin (ED-B) was expressed 
in atherosclerotic plaque, but not in normal blood vessels of humans and ApoE-/- mice. 
The binding to this ED-B could be utilized for a targeting domain (Dietrich et al. 2007). 
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Since T effector cell proliferation increased with the deprivation of IL-2, which 
exacerbates the chronic inflammation at atherosclerotic site, subsequent administration of 
IL-2 could re-adjust the homeostatic balance of regulatory T cells (Treg) and T effector 
cells (Dinh et al. 2012).  It was recently reported that the L19 antibody that specifically 
binds to ED-B was fused with interleukin-2 (IL-2). The Foxp3 and CTLA4 (Treg makers) 
were highly expressed after L19-IL2 treatment as compared to IL-2 only (p<0.03) 
(Dietrich et al. 2012). It indicated that IL-2 could be effectively delivered to the 
atherosclerotic plaque, resulting in the significant reduction of plaque size mediated by 
the increase in Treg.  
It is noteworthy that the immunosuppressive therapeutics could be exerted as the 
therapeutics is functionalized with specific binding moieties such as the protease 
specificity and a receptor mediated binding affinity. 
 
Induction of Autophagy to Treat Atherosclerosis  
Recent advances in characterizing the signaling cascades of MA revealed the 
machinery proteins that are particularly for autophagosome formation (Maiuri et al. 
2013). Especially, mammalian target of rapamycin (mTOR) plays a critical role in early 
and advanced atherosclerosis. Uptake of oxLDL by macrophages triggered cytoplasmic 
accumulation of lipid debris in early atherosclerosis (Brichkina and Bulavin 2012). If the 
expression of autophagy increased through the inhibition of mTOR, the lipid debris were 
fused with autophagosme and subsequently with lysosomes, resulting in producing free 
cholesterol. The free cholesterols were effluxed from the cell. As compared to early 
stage, the cholesterols were trapped inside lysosomes of foam cells. This is mainly due to 
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the increase in mTOR expression followed by the decrease in Atm expression. The 
prediction from these findings is that Atm-dependent inhibition of mTOR pathway at the 
molecular level could lead to activation of autophagy expression, resulting in the efflux 
of free cholesterol and rapid clearance by efferocytosis. The inactivation of mTOR 
pathway could provide a beneficial avenue for reduction of plaque size.  
It has been recently reported that diet-induced fat accumulation and induction of 
atherosclerosis could be explained by Wip1-Atm-mTOR signaling cascades in 
macrophages (Le Guezennec et al. 2012). in vivo data using Wip1-deficient mice showed 
that the transformation of macrophages into foam cells was suppressed. A noncanonical 
Atm-mTOR pathway regulated by Wip1-dependent signaling cascades was believed to be 
a novel target to treat atherosclerosis. Although immune-modulating therapy with 
specific targeting is promising, clear evidence and strategy to reduce immune-rejection 
after intravenous administration still demands.  
 
Nanoparticles Targeting to Atherosclerosis  
Advanced treatment for atherosclerosis has been introduced using nanotechnology 
(Park 2007). Drug delivery system (DDS) to release the therapeutics by the external 
stimuli has been extensively investigated in cancer and brain research (Bawa et al. 2009; 
Mura, Nicolas, and Couvreur 2013).  
It has been documented that use of narrowed blood vessel could be potential 
stimuli by which drug carrier will release the therapeutics in a targeted manner (Korin et 
al. 2012). Obstruction of blood vessels due to destruction of atherosclerotic plaque caused 
abnormally high shear stress. The study revealed that shear-activated microscale of 
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nanoparticle aggregates was broken up into nanoscale particulates by high shear stress by 
vascular narrowing. This strategy opened new stimuli responsive approach for treatment 
of atherosclerosis with minimized side effects while optimizing drug efficacy.  
Recent study demonstrated that specific enzyme present in atherosclerotic plaque 
could be an attractive option to achieve targeted drug delivery system. Nanoparticles 
were designed to be labile in presence of collagen IV (Col-IV), which specifically 
presented in plaque lesion (Fredman et al. 2015). Specific accumulation of nanoparticles 
at atherosclerotic lesions in LDLR-/- mice model fed with high western diet for 12 weeks 
were achieved in Col IV-Ac2-26 NPs as compared to Ac2-26 NPs (without Col IV 
peptide, KLWVLPK peptide). However, the homing rates of Col IV-Ac2-26 NPs to 
spleen and liver lower than that of NPs fabricated without Col IV peptide.  
 
Functionalized Cardiovascular Stents for Treatment of Atherosclerosis 
Implantation of DESs has shown positive outcomes as compared to BMS, 
resulting in decrease in the occurrence of in-stent restenosis (Bonaventura et al. 2012). 
Despite of promising clinical outcomes, recent studies reported that DES can cause late 
stent thrombosis and lead to long-term failure, especially after stenting complex lesions 
(Teirstein 2010). This was because anti-proliferative agents, such as Sirolimus or 
Paclitaxel, hindered not only SMCs migration, but also the re-endothelialization process 
of the substrate. That is why DES has been considered as ‘double-edged sword’. 
Functionalized cardiovascular stents will be discussed (Table 1).  
Rapid Endothelialization by Antibody-grafted Cardiovascular stent: Recently, antibody-
conjugated cardiovascular stent, which selectively captures circulating EPCs has shown a 
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remarkable improvement of re-endothelialization on metal surface (Li et al. 2014; 
Petersen et al. 2014; Benvenuto et al. 2015). This approach utilized circulating progenitor 
cells migrated on the surface of implanted devices, which already coated with specific 
antibodies, such as anti-human CD133 or CD34 antibodies (Yu et al. 2013; Song et al. 
2015; Li et al. 2014). To immobilize capturing antibodies on the metallic surface, various 
immobilization techniques, such as covalently binding to polymer basement and direct 
absorbing on metal surface, have been reported. The direct immobilization of capturing 
antibody on the metal stent has been considered an ideal approach, because it doesn’t 
cause any risks from the polymers on the stent (Yu et al. 2013).  
 
Nanoparticle-coated Cardiovascular Stent: Drug-eluted vascular stents (DES) prepared 
with conventional dip-coating or spray coating methods are widely used for angioplasty 
(Bonaventura et al. 2012). However, the therapeutics, such as Sirolimus, used for DES 
deteriorated the endothelialization process on the surface of metallic stents, resulting in 
late restenosis (Maisel 2007).  
Recent advances in nanotechnologies are poised to alter the development of 
implantable devices, such as bone replacement, dental implants and cardiovascular stent 
(Tomisa et al. 2011; Chaudhury et al. 2014; Nakano et al. 2009). The delivery of less 
invasive cardiovascular stent coated with nanoparticles (NPs) has been introduced 
(Nakano et al. 2009; Liu et al. 2014). NPs-coated stent (encapsulated with a fluorescent 
marker, FITC) has been formulated with an advanced technique called cation 
electrodeposition coating. in vitro cellular uptake study on cultured vascular SMCs 
demonstrated that NPs were taken up rapidly and efficiently as compared to FITC in the 
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absence of NP (Nakano et al. 2009). Fluorescent images of cross-sections of stent 
deployment sites in vivo porcine coronary artery for 2 weeks showed that NPs had played 
a beneficial role in prolonged delivery of drug and its distribution into the stented 
coronary artery.  
Another study demonstrated the efficacy of NPs-coated stent delivering N-
nitrosomelatonin (NOMela) (Liu et al. 2014). in vivo study on adult male Spraque-
Dawley rats revealed that stent coated with poly (D,L-lactide-co-glycolide) (PLGA, 
50:50)-nanoparticles containing NOMela significantly reduced platelet aggregation as 
compared to those deployed with the control stent, resulting in alleviating neointima 
formation.  
 
Electrophoretic deposition of Stem cells in Hydrogel: Hydrogels have been widely 
investigated for tissue engineering material, cosmetic purpose and pharmaceutical 
ingredients due to its high biocompatibility (Zhu and Marchant 2011; Parente et al. 2015; 
Peppas et al. 2000). Since the growth rate of implantable devices has substantially 
increased (Thevenot, Hu, and Tang 2008), development of metallic medical implants 
coated with hydrogels to alleviate inflammation would be a new era for researchers to 
rigorously investigate for future medicine. Among various implants, cardiovascular stents 
coated with hydrogels have been gradually introduced (Indolfi et al. 2011; Zhong et al. 
2009; Nakayama et al. 2001).  
To coat the metallic surface of stent with homogenous hydrogel layer formed, 
various strategies have been developed. Conventional methods were either simple dip-
coating approach or spray drying (Nakayama et al. 2001). Natural polymers including 
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chitosan and sodium alginate have intrinsic charges due to the presence of functional 
groups such as amine and carboxylic acid. It was developed that ITO (Indium Tin Oxide) 
glass was successfully coated with hydrogel using electrical potential (Cheng et al. 2012; 
Shi et al. 2009; Yang et al. 2010). The method indicated that the metallic surface can be 
coated with homogenous layer of hydrogels as polymer chains have shown proper 
electrical potential. In addition, three-dimensional (3D) patterning of human umbilical 
vein endothelial cells (HUVECs) deposited on ITO electrode by dielectrophoresis was 
reported. The study demonstrated that gelatin methacrylate (GelMA) was a promising 
hydrogel for use in cell encapsulation due to its high biocompatibility (Ramon-Azcon et 
al. 2012). GelMA deposited on ITO electrode with HUVECs was further polymerized as 
exposed to UV treatment, resulting in maintaining cell viability and growth over 7 days.  
Although deposition of hydrogel on the ITO electrode has been reported, proper 
scheme for metallic surface coating has not been developed. Recently, it has been 
developed that the metallic surface of cardiovascular stent can be coated with sodium 
alginate hydrogel containing adipose tissue derived mesenchymal stem cells (AD-MSCs) 
using electrophoretic deposition method (EPD) (Oh, Melchert, and Lee 2015). The study 
was aimed to develop the robust hydrogels mimicking “mud-and-straw” bird nest as cell 
delivery carrier for AD-MSCs. Mechanical property of hydrogels were tested using 
custom-built perfusive fluid channel, indicating that thiolated-sodium alginate in presence 
of poly (ethylene glycol)-diacrylate (PEGDA) blended with fragmented nanofiber pieces 
showed substantial increase in physical strength against pseudo-persfusive flow (1 
ml/sec). The results from cell viability and proliferation rates demonstrated that AD-
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MSCs were mostly viable after the cells encapsulated in hydrogels and then proliferated 
well during the incubation for 7 days.  
Apparently, stem cell encapsulation in hydrogels coated on metallic surface could 
be beneficial due to avoidance of autoimmune rejection against implantable device. 
Especially, cardiovascular stent coated with hydrogels containing stem cells will be next 
generation of stent. However, appropriate modification on hydrogels is required due to 
poor mechanical property of hydrogel. Moreover, behavior of encapsulated stem cells in 
hydrogels should be fully understood as stem niche decides the fate of differentiation and 
paracrine factor releases.  
 
Stem Cell Impregnated Nanofiber Stent: Nanofibers have been extensively studied to coat 
surface of implantable devices in various fields such as esophageal stent, aneurysm, 
tracheal regeneration and cardiovascular stent (Yoo et al. 2012; Park et al. 2011; Heo et 
al. 2011; Kuraishi et al. 2009; Oh and Lee 2014).  
Immunoregulatory function governed by paracrine factors released from stem 
cells offers advanced treatment for atherosclerotic plaque stabilization and regression (Z. 
Yang et al. 2010; Chen et al. 2008). In addition, the prolonging delivery of paracrine 
factors at atherosclerotic lesions will enhance the reparative response since paracrine 
factors can promote intrinsic repair mechanisms (Baraniak and McDevitt 2010; Gnecchi 
et al. 2008). To achieve prolonging treatment of paracrine factors, advanced cell delivery 
system is inevitable.  
It has been recently developed that MSCs were impregnated on nanofiber-coated 
stent sleeves (Hwang et al. 2015). MSCs were successfully seeded on nanofiber sleeves 
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produced by electrospinning technique (PLGA nanofibers) due to the increase in surface 
area. Also, seeded-MSCs were over-coated with another nanofiber sleeves, resulting in 
that overcoated sleeves protected seeded-MSCs from not only being rapidly washed out 
by perfusive flow after the angioplasty, but also being deteriorated by autoimmune 
rejections from our body. This approach paved the way for in vivo studies to investigate 
the efficacy of stem cell impregnated nanofiber stent on pig umbilical artery. According 
to the results, locally release of paracrine factors such as VEGF and HGF from delivered 
MSCs would reverse the progression of atherosclerosis.  
  
	 30 
Table 1. Delivery Methods for Stem Cell Therapy against Atherosclerosis. 
 
 Description Application Significances Ref 
In
je
ct
io
n Injection 
of Stem 
Cells 
 
Atherosclerotic 
renal artery 
stenosis (ARAS) 
Increased expression of paracrine 
factors such as VEGF, FLK-1 and 
HIF-1α 
Additional intervention required to 
reduce oxidative stress 
(Ebrahi
mi et al. 
2013) 
Atherosclerotic 
vulnerable plaque 
Downregulation of cytokines such as 
TNF-alpha, hs-CRP and IL-6 in 
serum 
(Wang 
et al. 
2015) 
Prevention of 
progression of 
atherosclerosis 
in vivo Infusion of MSCs alleviated 
endothelial dysfunction and plaque 
progression in ApoE
-/-
 
(Lin et 
al. 2015) 
A
b-
g-
st
en
t Capture 
circulating 
progenitor 
cells 
 
Rapid 
endothelialization 
on metallic 
surface 
After deployment of CD34-g-stent 
in vivo, EPCs (CD34+) adhered to 
CD34-g-stent much earlier and 
proliferated faster in presence of 
anti-CD34 antibody 
(Yu et 
al. 2013) 
in vivo arteriovenous shunt model 
showed CD133-g-stent captured 
CD133+ from the blood stream 
within 6 hr 
(Li et al. 
2014) 
St
en
t-c
oa
te
d 
w
ith
 st
em
 
ce
lls
 Local 
delivery of 
stem cells  
Localized 
delivery of AD-
MSCs  
Sodium alginate hydrogels 
containing AD-MSCs were 
successfully deposited on metallic 
stent via EPD 
(Oh, 
Melchert
, and 
Lee 
2015) 
Prolonging 
delivery of 
paracrine factors 
(PFs) released 
from pMSCs 
in vivo deployment of pMSCs-
impregnated NFs-coated stent 
showed no thrombotic occlusion or 
immune rejection 
(Hwang 
et al. 
2015) 
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2.4. Nanographene Carriers  
Nanographene  
Graphene can be considered as a flat monolayer of carbon atoms. Graphene 
tightly packed into a 2D honeycomb lattice is the initial building block of carbon 
nanotubes (CNTs), graphite and fullerenes.  
Graphene has drawn a high level of interest in various fields including electrical 
engineering, computer science, chemical engineering and biomedical research because it 
has light weight, single-atom thickness, versatile mechanical capability and optical 
property. Moreover, graphene can be effectively modifiable with interest molecules via 
chemical reaction.  
Nanographene was reported to be an excellent material for biomedical researches, 
such as electric vehicles, conductive implants and tissue engineering. The biocompatible 
and flexible electronic sensors using graphene are feasible due to high intrinsic strength 
(42 Nm−1), high Young’s modulus ratings (1 TPa), and graphene-to-substrate interfacial 
adhesion (adhesive energy of 0.45 Jm−2 on SiO2). Graphene field effect transistors (FETs) 
showed enormous potential as basic material for analog and high-frequency circuits. 
Moreover, graphene sensor arrays selectively screen bifunctional peptides and are proven 
to be cost effective. 
Nanographene as Photothermal Therapy 
Photothermal therapy irradiated by external laser damages the pathogenic cells. A 
laser is a main source for irreversible damage to the target cell by converting light to heat. 
Photothermal therapy has been extensively reported for cancer treatment due to its 
selective therapeutic efficacy by laser irradiation (Yang et al. 2012; Bian et al. 2014). 
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Nanomaterials including gold nanorods or nanoparticles for photothermal therapy have 
been studied for cancer and rheumatoid arthritis treatment (Lee et al. 2013; Raeesi and 
Chan 2016; Yang et al. 2015). 
Owing to their unique physicochemical properties, graphene derivatives such as 
graphene oxide (GO), reduced-GO (rGO) and ligand-conjugated rGO recently have a 
great potential in biomedicine (Yang et al. 2013). Graphene-based photothermal therapy 
has been gradually reported due to the intrinsic near-infrared (NIR) optical absorbance. It 
has been reported that graphene-based nanocomposite with a variety of inorganic 
nanoparticles such as gold or silver can achieve interesting optical property, resulting in 
multi-modal imaging and imaging-guided cancer therapy. The photothermal activity of 
nanographene was modifiable by controlling the shape and size of inorganic 
nanostructures. Ultrasmall gold nanoparticle-graphene nanocomposites efficiently 
converted NIR light to heat up to 80 °C within 10 min (Zedan et al. 2013). However, the 
converted heat can travel across the tissue, resulting in unwanted tissue damage or cell 
apoptosis.  
The targeted delivery system made of nano- or biomaterials is necessary to 
improve drug efficacy in the treatment of various diseases (Jin, Jin, and Hong 2014). It 
has been recently reported that aptamer-gold nanoparticle-graphene oxide nanocomposite 
displayed a great photothermal activity to MUC-1 positive human breast cancer cells 
(MCF-7) under the NIR irradiation (Yang et al. 2015). Due to gold nanoparticles on 
graphene oxide, it showed a high conversion efficacy of light to heat. In addition, the 
functionalization of aptamer on nanocarriers achieved specific targeting capability, 
resulting in high specific ablation of nanocarriers containing MCF-7.   
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Since graphene or nanographene have drawn great attention from the  biomedical 
research field, in vivo biodistribution and toxicology of nanocarriers upon intravenous 
injection should be thoroughly investigated. The in vivo biodistribution and toxicity of 
nanographene sheets (NGS) and nanographene functionalized with polyethylene glycol 
(PEG) have been systemically investigated after intravenous administration (i.v. 
administration) (Yang et al. 2011). It was found that PEGylated-NGS didn’t cause 
significant systemic toxicity up to dose of 20 mg/kg. PEGylated-NGS after i.v. 
administration were mainly accumulated in the liver and spleen via the 
reticuloendothelial system (RES). The ourcomes of in vivo biodistribution and toxicology 
study of nanographene suggested that its efficacy can be further improved by applying 
PEG onto the plane of nanograene sheets. 
Although early lesional macrophage apoptosis has a positive effect on regression 
of plaque, there was no effective approach to induce apoptosis with single-cell 
specificity. It was previously proposed that photothermal therapy using single-walled 
carbon nanotubes (SWCNTs) induced thermal destruction of macrophages after the NIR 
laser irradiation (Kosuge et al. 2012).  
Nanographene as Imaging Agents 
The intrinsic NIR photoluminescence of nanographene can serve as a new class of 
advanced sensing system (Wen et al. 2014; Yang et al. 2013). It has been reported that 
nanographene oxide (NGO) sheet loaded with hydrophobic drugs, such as doxorubicin 
via simple hydrophobic interaction between doxorubicin and the plane of NGO, was 
utilized for live cell imaging with the targeted property (Sun et al. 2008). The results 
indicated that anti-cancer drug delivery via NGO functionalized with antibody for 
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selective binding to cancer cells offers imaging-guided drug delivery for biological and 
medical applications. In addition, in vivo biodistribution of graphene oxide functionalized 
with PEG was tracked by fluorescence imaging (Rong et al. 2014).  
As compared to other imaging techniques including single-photon emission 
computed tomography and positron emission tomography (PET), photoacoustic 
tomography or imaging (PAT or PAI) has been extensively studied due to its non-
invasive imaging modality (Yang et al. 2007). PAT is a novel imaging modality with 
high spatial resolution images and it can provide optical contrast deep in biological tissue. 
It was reported that strong PA signals were captured from reduced-graphene oxides or 
graphene (Patel et al. 2013). Because reduced-nanographene cannot be luminescent, the 
optical illumination by NIR laser would generate regional heat to trigger molecular 
vibration, which can be further utilized for the generation of wave sound or acoustic 
sound.  
Gadolinium (Gd3+), a paramagnetic metal ion, is considered as a dominant agent 
for MRI (Ananta et al. 2010). However, advanced material that is more efficacious than 
clinical Gd3+ chelate-based agents is still highly demanded.  It has been suggested that the 
size, architecture and shape of nanographene can be regulated to achieve magnetic 
property and high relaxivity (Paratala et al. 2012). Graphene-based magnetic resonance 
imaging contrast agent has been developed (Kanakia et al. 2013; Paratala et al. 2012) and 
demonstrated a great potential as high relaxivity MRI contrast agent. Nanographene 
intercalated with Mn2+ was further improved by the functionalization with dextran 
(Kanakia et al. 2013) which could prevent non-specific interaction with blood and 
showed very high solubility (up to 100 mg/ml) in deionized water and biological buffers.  
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As a result of the continuous application of both invasive as well as noninvasive 
imaging modalities to elucidation of the associated vessel wall changes during 
atherosclerosis, cardiovascular imaging using nanographene rapidly and impressively 
evolves for diagnostic and therapeutic purposes. 
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CHAPTER 3 
DEVELOPMENT OF MANNOSYLATED-REDUCED GRAPHENE OXIDES FOR 
TARGETED MACROPHAGE ABLATION 
 
3.1. Rationale 
Macrophages constitute about 20% of the cells within atherosclerotic lesions, and 
thus have served as a key component of atherogenesis (McCarthy et al. 2010). Previous 
studies revealed that there were opposing roles of apoptosis in atherosclerotic plaque 
progression (Seimon and Tabas 2009). Early lesional macrophage apoptosis has overall 
positive effects on atherosclerosis owing to the capability of phagocytes to proficiently 
clear the dead macrophages (Moore and Tabas 2011; Tabas 2005; Tabas 2010). In 
contrast, macrophage apoptosis in advanced lesions would be harmful due to the 
defective phagocytic clearance (Taylor et al. 2000). The necrotic debris along with 
stresses on the fibrous cap imposed by the physical nature of the necrotic core (Ohayon et 
al. 2008) (i.e. the secondary necrosis of the macrophage) were known to contribute to 
acute inflammatory response and thrombus (Tabas 2010; Tabas 2005). 
The macrophage-targeted photodynamic therapy which uses light actuate 
molecules has offered an efficient remedy against atherosclerosis implicated with 
physiologically undesirable macrophage subtypes (Li and Glass 2002). Previous drug and 
ligand binding studies revealed overexpression of mannose receptors (MRs) in a subset 
of macrophages (M2) (Tahara et al. 2014; Mantovani, Garlanda, and Locati 2009), 
implying that MRs in high-risk plaques could serve as a proper target for the treatment 
against early and advanced stages of atherosclerotic plaque (Tahara et al. 2014). 
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Graphene oxides (GOs) have received a great attention from various biomedical 
fields, such as tissue engineering (Wang et al. 2012; Elkhenany et al. 2015), drug 
delivery (Zhang et al. 2014; Xu, et al. 2014) and bio-imaging technologies (Wen et al. 
2014; Bian et al. 2014). The intrinsic optical properties of GO including NIR absorption 
have been utilized in photothermal applications (Meng et al. 2014; Robinson et al. 2011; 
Tao et al. 2014; Yang et al. 2012). The thermal ablation induced by single-walled carbon 
nanotubes (SWNTs: roll-up graphene sheets) applied with NIR laser efficiently 
eradicated macrophages (Kosuge et al. 2012). Although they have achieved a significant 
reduction of macrophages in atherosclerotic plaque, the non-specific uptake property of 
SWNTs damaged other organs, particularly liver, requiring extensive studies on 
enhancement of its targetability. The distinctive efficacy of GOs on reduction of 
macrophage plaque warrants further investigation on the clinical application of reduced 
GO (rGO) to the treatment of inflammatory atherosclerosis.  
We have designed and evaluated a smart nano-system which targeted 
photothermal ablation of M2-macrophages overexpressed in atherosclerotic plaques. The 
microwave-assisted reduction of GOs was explored for a facile synthesis of 
polyethyleneimine-reduced GO (PEI-rGO), whereas the mannose functionalization 
(Man-rGO) offers targeting specificity toward macrophage. The cell viability upon 
exposure to Man-rGO was examined using both LDH assay and AlamarBlue assay, and 
the targeting efficacy of Man-rGO was assessed using its cellular uptake rate by M2-
polarized (i.e., which is induced by IL-4) macrophage.   
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3.2. Materials and Methods 
Materials 
Graphite flakes (Nano19) was a gift from Ashbury Carbons (Asbury, NJ). 
Potassium permanganate (KMnO4), polyethyleneimine (PEI, branched, Mn=12k), nitric 
acid (HNO3), sulfuric acid (H2SO4), phosphoric acid (H3PO4), hydrogen peroxide (H2O2), 
D-(+)-mannose, sodium borohydride (NaBH4), nile-red (NR), sodium nitrite, 
dichloromethane and ninhydrin were purchased from Sigma-Aldrich.  
Mouse macrophage cell line (Raw264.7), Dulbecco’s modified eagle’s medium 
(DMEM) (30-2601) and penicillin-streptomycin solution (30-2300) were purchased from 
ATCC. Fetal bovine serum (FBS) was purchased from Atlantic biologicals. All other 
reagents and solvents were of analytical grade. 
 
Preparation of Mannosylated-reduced Graphene Oxide (Man-rGO) 
Mannosylated-reduced graphene oxide (Man-rGO) was synthesized using three 
step procedures: (1) preparation of ox-GOs, (2) microwave-assisted synthesis of PEI-
rGOs and (3) mannosylation of PEI-rGO using reductive amination reaction (Man-
rGOs).  
(1) Preparation of Oxidized Graphene Oxides (ox-GOs): Graphene oxides (GOs) were 
fabricated using the modified Hummers method (Marcano et al. 2010). Nano-sized GOs 
were obtained from large pieces of GOs by being oxidized under the strong acidic 
environment (Jin et al. 2013). GOs (30 mg) dispersed in 40 ml of H2SO4 and HNO3 
solution (3M of H2SO4 and 1M of HNO3) were bath-sonicated for 3 hr and then refluxed 
at 120 °C for 24 hr. The suspension was centrifuged at 20,000 rpm for 30 min and the 
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precipitations were reconstituted in 30 ml of DI water. The solution was dialyzed using a 
dialysis tubing (3,500 MWCO) to remove the trace amount of metal ions. After dialysis, 
the oxidized GOs (ox-GOs) were adjusted to the pH 7 and kept at 4 °C until further usage.  
(2) Preparation of Polyethyleneimine-reduced Graphene Oxides (PEI-rGOs): The pre-
synthesized oxidized-GOs (50 mg) in 20 ml of distilled water were mixed with 250 mg of 
PEI in a glass beaker. The solution was mechanically shaken up using a homogenizer 
(IKA, NC) until clear solution was obtained. The mixture was heated for 6 min in 
microwave oven at a power of 480 W. After mild sonication of the product containing 
black transparent suspension and black large precipitates for 10 min, the solution was 
centrifuged (3,000 rpm) for 20 min. After removing the precipitates, the black transparent 
suspension (PEI-reduced GOs, PEI-rGOs) was dialyzed using a dialysis bag (15k 
MWCO) for 3 days to remove unreacted PEI.  
(3) Synthesis of Mannosylated-Graphene Oxides (Man-rGOs): 100 mg of mannose was 
added into 20 ml of 0.5 M sodium acetate buffer containing 25 mg of PEI-rGOs. The 
solution was stirred at room temperature for 24 hr, and added with 2mg of NaBH4. The 
mixture was stirred for another 30 min. The products were dialyzed against DI water in a 
dialysis tube (3,500 MWCO) for 3 days to remove unreacted mannose and reducing 
agents. After dialysis, the solution (Man-rGOs) was kept at 4 °C for further use.  rGOs 
(i.e., a control) were prepared with the same method as that used for the preparation of 
PEI-rGOs except an addition of PEI in pre-oxidized GOs solution.  
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Characterization of Formulations 
Morphological properties were characterized using transmission electron 
microscopy (TEM). Water suspension of graphene formulations was mounted on copper 
grids deposited with carbon film and air dried, then particle distribution was observed 
using TEM CM12 (FEI, Hillsboro, OR) at 80 kV accelerating voltage. Fourier transform 
infrared spectroscopy (FTIR) assay was performed using Cary 630 FTIR (Agilent, Santa 
Clara, CA) at a resolution of 4 cm−1 and obtained results were analyzed using the 
attenuated total reflectance technique (ATR). As described previously, the derivatization 
process with ninhydrin was used to determine the amount of -NH2 groups in oxGO, rGO, 
PEI-rGO and Man-rGO (Oh, Melchert, and Lee 2015). The concentration of the solution 
was spectrophotometrically calculated at the absorbance of 540 nm (Spectronic 20D, 
ThermoScientific, Waltham MA). The UV-vis-infrared spectra were obtained at room 
temperature using a spectrophotometer (Spectronic 20D, ThermoScientific, Waltham 
MA).  
 
Assessment of the Cellular Uptake Rate 
A pre-determined number of cells (1x105 in 200 µl of media) was seeded in 96-
well plate and incubated for overnight until cells were fully attached. Raw 264.7 were 
treated with the formulations, such as rGO, PEI-rGO and Man-rGO, labeled by NR (1 
µg/ml) and incubated for 5 min, 15 min, 1, 2 and 4 hr. For the quantitative assessment 
study, 0.2% of Tween-80 in PBS was added into each well to lyse the cells. The 
fluorescent intensities of NR were then measured using the multimode detector (Ex: 565 
nm and Em: 625 nm).  
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For fluorescent microscopy, the cells along with test formulations were incubated 
for 1 hr and washed several times with PBS. The cells were fixed with 4% of 
paraformaldehyde for 10 min and then allowed to be permeabilized by Tween-80 (0.5%) 
for 30 min at 4 °C. Nuclei were stained with DAPI (300 nM) (Life Technologies, Grand 
Island, NY). The fluorescent microscopy (Leica DMI 3000D, IL) images of the samples 
were observed under the absorbance intensities of NR (Ex:  535 nm, Em: 625 nm) and 
DAPI (Ex:  358 nm, Em: 461 nm). 
 
Photothermal Ablation of Raw 264.7 using NIR Laser 
The testing formulations, such as rGO, PEI-rGO and Man-rGO, were dissolved in 
each cell medium at a concentration of 1 µg/ml and incubated for 1 hr. Each well was 
irradiated by a portable NIR laser (808 nm, Armlaser, San Francisco, CA) with a power 
density of 1 W/cm2 at pre-determined intervals (0, 2, 4, 6, 8 and 10 min). Then, 100 µl of 
cell media were mixed with LDH reagent (i.e. Homogenous membrane integrity assay) 
according to the direction given by the company (Promega, Madison, WI).  
 
Statistical Analysis 
Data were presented as mean±standard deviation (SD). One-way analysis of 
variance (ANOVA) followed by tukey’s HSD as a post-hoc analysis was utilized to 
determine statistical significance between groups. P value was determined using SPSS 
software (SPSS, Chicago, IL) and P values of less than 0.05 were considered as 
statistically significant. All experiments were conducted in triplicate unless otherwise 
specified.   
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3.3. Results and Discussions 
Fabrication of Man-rGO 
Oxidized-graphene oxide (ox-GO) was synthesized from graphite powder 
(Nano99, Asbury carbon, NJ) using a modified Hummer’s method (Marcano et al. 2010). 
The reduction process of ox-GO in the presence of PEI was explored to promote 
microwave-assisted facile reaction (Figure 6). For the synthesis of Man-rGO, the 
reductive amination reaction of PEI-rGO in the presence of mannose was employed as 
shown in Figure 6.  
 
Assessment of ζ-Potential	for the Optimization Process of Synthesized PEI-rGO 
The passivation time of ox-GO was measured as one of the optimization variables 
for synthesized PEI-rGO. It was found that PEI-rGO had a positive ζ-potential when they 
are hydrothermally treated using microwave (Figure 7). PEI-rGO after 1 min of the 
surface passivation by microwave yielded a prompt change in the ζ-potential (25.2±2 
mV). During the incubation period, the ζ-potential of PEI-rGO gradually increased up to 
31.6±2.5 mV, however, in the absence of PEI, the ζ-potential of rGO remained negative 
until the reaction terminated.   
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Figure 6. Schematic illustration of three step procedure of the preparation of Man-rGO 
((a) nanographene carrier, (b) PEI linker between the carrier and targeting moiety and (c) 
targeting moiety (mannose-functionalization)).  
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Figure 7. ζ-potential of oxGO and PEI-rGO at different passivation times (n=3).  
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Effects of Amine Density on Passivation Time 
As PEI has a sufficient amount of primary amine (–NH2), ninhydrin assay was 
performed to assess the amine density and its effects on passivation time. ox-GOs 
initially had none or minimal –NH2 density (Figure 8), but their NH2 density gradually 
increased (0 min: (0.03±0.03) x10-2 mg/ml and 1 min: (6.27±0.96) x10-2 mg/ml) during 
the passivation process (480 W). The reaction rate of ox-GO with PEI reached a plateau 
at 4 min and remained constant for the rest passivation process (i.e., up to 6 min) (4 min: 
(15.4±0.6) x10-2 mg/ml, 5 min: (15.4±0.3) x10-2 mg/ml and 6 min: (15.4±0.3) x10-2 
mg/ml). The images of PEI-rGO solution displayed optical color changes (yellow brown 
to dark black), as the ox-GO reacted with PEI under various microwave passivation 
conditions.  
 
Absorbance Spectra of PEI-rGO in Near-Infrared (NIR) Region 
The reaction between ox-GO and PEI under microwave-assisted passivation 
caused the significant changes in the absorbance profiles of the NIR region (Figure 9). 
Although ninhydrin assay displayed an increase in amine density, there were no 
significant changes in the light absorbance during the incubation period of 2 min. After 
the incubation for 4 min, however, the level of light absorbance increased, indicating that 
the incubation time is one of the main factors that determine complete reaction between 
ox-GO and PEI. The level of absorbance reached a plateau after 4 min that was in a close 
agreement with the results of ninhydrin assay.  
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Figure 8. Effects of passivation time on the amine density (n=3). Inset: Status of PEI-rGO 
solution with varying passivation times.  
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Figure 9. Absorbance spectra of PEI-rGO in near-infrared (NIR) region.  
 
 
  
	 48 
Characterization of Mannosylated-Graphene Oxide (Man-rGO) 
To confirm that the mannosylation of PEI-rGO could be carried out via reductive 
amination reaction, the changes in amine density were examined using ninhydrin assay 
(Figure 10). Both PEI-rGO and Man-rGO had a high density of primary amine as 
compared to ox-GO and rGO, and between them Man-rGO had a lower density of 
primary amine than PEI-rGO (PEI-rGO: 15.4±0.3) x10-2 mg/ml and Man-rGO: 
(7.21±0.13) x10-2 mg/ml).  
Because amine groups present in PEI interact with mannose, the changes in ζ-
potential signify electrophoretic mobility of the charged surface. ζ-potential of PEI-rGO 
was +30.6±3.3 mV, whereas ζ-potential of Man-rGO was down to +13.1±3.8 mV upon 
being interacted with mannose mainly due to the conjugation of mannose on the PEI-rGO 
surface via reductive amination process (Figure 10).  
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Figure 10. Assessment of changes in the amine density before and after mannose-
functionalization (** indicates a significant difference as compared to ox-GO and PEI-
rGO, n=3, p<0.01). ζ-potential of such formulations as oxGO, rGO, PEI-rGO and Man-
rGO was presented in the Figure (below).  
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in vitro Assessment of Light-to-Heat Conversion  
The results of UV-vis-NIR spectra of ox-GO, rGO, PEI-rGO and Man-rGO 
suspensions (10 µg/ml in PBS, pH=7.4) are closely correlated with their visual images 
(i.e., colors). The reduction of ox-GO (rGO or PEI-rGO) by microwave-passivation 
exhibited a significant increase in NIR absorption at 808 nm by 5 to 10 folds as 
compared to that of ox-GO (Figure 11). The absorbance value for PEI-rGO beyond the 
NIR spectral region was much greater than that for rGO, indicating that the addition of 
PEI during the microwave passivation process accelerated the reduction of ox-GO. Man-
rGO upon mannosylation also displayed the similar absorbance profile to PEI-rGO.  
To assess the light-to-heat conversion efficacy of Man-rGO, the solution 
temperature irradiated by NIR laser (808 nm, 1 W/cm2) for 5 min was recorded (Figure 
12). NIR irradiation enhanced the temperature of Man-rGO solution up to 45 °C, whereas 
there were no substantial changes in the temperature of ox-GO and rGO groups. Thus, 
judging from the distinctive increase in the absorption profiles beyond the NIR spectral 
region, it can be concluded that Man-rGO is more effective than ox-GO or rGO in 
photothermal ablation triggered by the NIR laser irradiation (808 nm). 
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Figure 11. UV-vis-NIR spectra of oxGO, rGO, PEI-rGO and Man-rGO at the 
concentration of 10 µg/ml.  
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Figure 12. Temperature change curves of oxGO, rGO and Man-rGO solutions examined 
at the 808 nm laser with a power density of 1 W/cm2.  
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Morphological Characterization of Test Formulations  
The morphology of rGO, PEI-rGO and Man-rGO was visualized by TEM as 
shown in Figure 13. In the TEM images of rGO, a large size of dark dots was clearly 
detected (1.62±4.7 µm). As compared to rGO, individual small particles were found on 
both PEI-rGO and Man-rGO images (68.1±9.8 nm and 78.8±10.8 nm, respectively). A 
size of GO decreased as GO was oxidized under strong acidic conditions (GO: 1.12±2.8 
µm and ox-GO: 162.8±21.8 nm, respectively). As oxGO was passivated to produce rGO 
in the absence of PEI, the size of rGO substantially increased due to the rapid 
aggregation of rGO. The overall size of PEI-rGO was smaller than that of rGO, 
indicating that PEI played an essential role in preventing the formulations from being 
rapidly aggregated.  
The IR spectra of ox-GO, rGO, PEI-rGO and Man-rGO are shown in Figure 14. 
ox-GO exhibited a broad peak at about 3200-3500 cm-1, which is attributed to the 
hydroxyl groups (-OH). Several peaks at 1734 cm-1 (C=O), 1394 cm-1 (O-H deformations 
in the C-OH groups), 1285 cm-1 (C-OH stretching vibration) and 1065 cm-1 (C-O 
stretching vibration in C-O-C in epoxide) were also detected. After microwave-assisted 
reduction, the peak intensity level of the C-O stretching vibration of epoxide groups in 
rGO became distinctively low, whereas those of the oxygen functional groups in rGO 
were high, indicating that rGO was partially reduced during the passivation process.  
The PEI-rGO had a prominent peak at 1634 cm-1 which is attributed to amide 
linkage (C=O stretching in amide groups). The broad absorption peak of amines around 
3250 cm-1 (N-H) was also appeared. For Man-rGO, the reductive amination reaction led 
to the formation of Schiff’s base (R-CH=N-R bond) which was confirmed by the 
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presence of C=N stretch at 1410 cm-1. In addition, the greater number of amide linkages 
were formed through reductive amination reaction between PEI-rGO and mannose which 
was represented by the stronger peak at 1634 cm-1. 
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Figure 13. TEM images of GO, rGO, PEI-rGO and Man-rGO. Size of formulations was 
measured by dynamic light scattering (DLS, Malvern, UK) (GO: 1.12±2.8 µm, rGO: 
1.62±4.7 µm, PEI-rGO: 68.1±9.8 nm and Man-rGO: 78.8±10.8 nm).  
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Figure 14. FT-IR spectra of oxGO, rGO, PEI-rGO and Man-rGO. The strong peak at 
1634 cm-1 and peak at 1410 cm-1 clearly indicate the presence of amide linkage (C=O 
stretching in amide groups) and formation of Schiff’s base (R-CH=N-R bond), 
respectively. 
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Cell Viability Study  
The potential cytotoxicities of rGO, PEI-rGO and Man-rGO were assessed using 
both LDH and AlamarBlue assays (Figure 15 and 16). As shown in Figure 15, all test 
formulations after the incubation for 48 hr exerted only 10% of membrane disintegration. 
However, over 60% cells were dead upon being treated with 100 µg/ml each of PEI-rGO. 
For AlamarBlue study (Life technologies, Grand Island, NY), over 90% of cell viability 
were maintained at the concentrations (up to 10 µg/ml) of all tested formulations (Figure 
16). Both LDH and AlamarBlue assays demonstrated that accelerated apoptosis occurred 
in cells upon being exposure to all formulations at the concentrations above 100 µg/ml. 
The low concentrations (0.01 to 0.1 µg/ml) may not be sufficient enough to cause light-
to-heat conversion, whereas the high concentrations (i.e. greater than 3 µg/ml) could 
exert a potential cytotoxicity. Therefore, the concentration (1 µg/ml) which retains 
almost 100 % of cell viability was selected for continuous studies. 
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Figure 15. Cytotoxicity of rGO, PEI-rGO and Man-rGO in M2-macrophages measured 
by LDH.  
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Figure 16. Cytotoxicity of rGO, PEI-rGO and Man-rGO in M2-macrophages measured 
by AlamarBlue assay.  
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in vitro Cellular Uptake Study  
To study the endocytosis process of macrophages induced by IL-4 mediated M2 
polarization, the uptake rates of such formulations as rGO, PEI-rGO and Man-rGO were 
investigated (Figure 17). As IL-4 is a well-known inducer of M2 phenotype macrophage, 
the cells were pre-incubated with IL-4 (20 ng/ml) for 24 hr. Data were presented with the 
changes in ΔRFUs (Relative Fluorescent Units) (ΔRFUs=RFUs(+IL-4)–RFUs(-IL-4)) as a 
function of incubation times. A high ΔRFUs of M2 phenotype macrophage was observed 
from Man-rGO polarized with IL-4 (ΔRFUs=1.66±0.46 at 1 hr incubation) (Figure 17). 
However, no significant changes were observed from PEI-rGO and rGO (ΔRFUs for 
PEI-rGO=0.17±0.1 and for rGO=0.1±0.08 at 1 hr incubation). A great amount of Man-
rGO was uptaken by M2-polarized macrophage due to the overexpression of mannose 
receptors on the cell surface, which was in a close agreement with the previous reports 
(Chaubey, Patel, and Mishra 2014; Ruan et al. 2014; Tahara et al. 2014). 
To further validate the mannose-receptor mediated uptake process of Man-rGO, 
cells were pre-incubated with varying amounts of mannose functioning as a receptor-
binding competitive inhibitor. It was demonstrated from the cell viability study that the 
pre-incubation of cells with mannose (0 to 1 mg/ml) exerted no significant cytotoxicity 
(Figure 18). Pre-incubation of mannose lowered the uptake rate of Man-rGO in a reverse 
concentration dependent manner, indicating that Man-rGO was endocytosized through a 
specific mannose receptor-dependent internalization process (Figure 19). The fluorescent 
microscopy images of cells after 1 hr incubation (Figure 20) revealed that Man-rGO were 
mainly accumulated at the subcellular level where the mannose receptors were 
sufficiently expressed.  
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Figure 17. in vitro Cellular uptake rate of fluorescently labeled rGO, PEI-rGO and Man-
rGO by Raw 264.7 and IL-4-activated Raw 264.7. Data presents the changes in ΔRFUs 
(Relative Fluorescent Units) (ΔRFUs=RFUs(+IL-4)–RFUs(- IL-4)) with varying incubation 
times (** indicates a significant difference between the groups, p<0.01).  
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Figure 18. Assessment  of cytotoxicity of mannose at different concentrations (0, 0.2, 0.4, 
0.6, 0.8 and 1 mg/ml). No statistical difference was observed all the concentration levels.  
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Figure 19. The cellular uptake rate of Man-rGO by M2-macrophages in the presence of 
competitive mannose inhibitors at 0, 0.2, 0.4, 0.6, 0.8 and 1 mg/ml (n=3).  
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Figure 20. Fluorescent images of the intracellular uptake amount of fluorescently labeled 
rGO, PEI-rGO and Man-rGO after the incubation for 1 hr. White scale bars indicate 200 
µm.  
 
 
 
 
 
 
 
 
 
	 65 
 
Photothermal Ablation of Macrophage using NIR Laser 
To induce photothermal ablation of macrophages, they were exposed to near-
infrared (NIR) radiation (808 nm) for 2 min. Macrophages upon exposure to NIR 
treatment in the presence of Man-rGO displayed a significant cell disruption ((-) NIR: 
100±8.6%; (+) NIR: 85.9±8.7%, n=9, p<0.01) (Figure 21), whereas the cells in the 
presence of rGO or PEI-rGO showed no significant differences in cell viability between 
NIR treated and NIR non-treated (For rGO, (-) NIR: 100±9.6%; (+) NIR: 97.1±9.4%, 
n=9, p=0.51 and For PEI-rGO, (-) NIR: 100±8.6%; (+) NIR: 92.6±9.5%, n=9, p=0.1). 
Thus, it can be concluded that Man-rGOs are suitable for photothermal ablation of M2-
macrophages due to the greatest cellular uptake rate by macrophages among testing 
formulations. As the exposure time increased up to 10 min, the apoptosis rate of 
macrophages upon exposure to Man-rGO increased. After the treatment for 10 min, only 
36.8± 7.1% of macrophages were viable as shown in Figure 22. It can be concluded that 
photothermal ablation of macrophages were feasible with Man-rGO which has the 
highest cellular uptake rate and strongest NIR absorption property among tested 
formulations. 
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Figure 21. Photothermal Ablation of Macrophage caused by NIR Laser. Cell viability 
after NIR irradiation for 2 min. M2-macrophages with Man-rGO after NIR treatment for 
2 min displayed a significant disruption (** indicates a significant decrease in cell 
viability, n=9, p<0.01).  
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Figure 22. Time-dependent photothermal ablation of macrophage.  
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Tagetability of Photothermal Ablation in Macrophage  
To study the targetability of the formulation, mast cells (RBL-2H3, ATCC), a part 
of immune system in the atherosclerotic plaque, were selected as a comparative group 
against macrophages. It was recently reported that mast cells have played an essential 
role in induction of endothelial cell apoptosis (Willems et al. 2013; Bot, van Berkel, and 
Biessen 2008; Oh and Lee 2014). As apoptotic cells release a large amount of cytokines 
(i.e. TNF-α (tumor necrosis factor-α), IFNγ (interferon-γ)) and histamine, any changes in 
viability of activated-mast cells can cause the onset of atherosclerotic plaque (Swindle 
and Metcalfe 2007; Sun et al. 2007). The cellular uptake rates of mast cells were much 
lower than those of macrophages mainly possibly due to the lack of the mannose 
receptors in mast cells (Figure 23). The cell viability of macrophages significantly 
decreased upon exposure to Man-rGO irradiated with NIR, whereas there were no 
changes for mast cells (macrophage: 67.8±1.3%, mast cells: 98.3±0.3%, p<0.01) (Figure 
24), indicating that Man-rGO probably serves as a platform which has a powerful 
targetability toward the mannose receptors. 
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Figure 23. in vitro Cellular uptake rate of fluorescently labeled Man-rGO by M2-
macrophages and RBL-2H3.  
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Figure 24. Cell viability of M2-macrophages and RBL-2H3 upon exposure to Man-rGO 
irradiated with NIR for 6 min (** indicates statistical difference between two groups, 
n=3, p<0.01). 
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3.4. Conclusion 
A simultaneous microwave-assisted synthesis of PEI-rGOs and mannosylation of 
PEI-rGO using the reductive amination reaction is adopted to successfully synthesize 
mannosylated-reduced graphene oxide (Man-rGO) with the specific surface property and 
super-capacity photothermal ablation activity. The fluorescent microscopy images of 
cells after 1 hr incubation demonstrated that Man-rGOs were mainly accumulated at the 
subcellular level where the mannose receptors were overexpressed. There was a 
significant decrease in the cell viability of macrophages upon exposure to Man-rGO 
irradiated with NIR. The super capacitive photothermal ablation activity of Man-rGO 
triggered by the NIR laser irradiation is ascribed to its enhanced ζ-potential and the 
presence of the greater number of amide linkages. It was concluded that Man-rGO had an 
enhanced targetability toward the mannose receptors, which can be explored as an 
efficient treatment strategy against atherosclerosis.  
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CHAPTER 4 
DEVELOPMENT OF THIOLATED-GRAPHENE QUANTUM DOTS FOR DOWN-
REGULATION OF LIPID ACCUMULATION AND ROS PRODUCTION 
 
4.1. Rationale 
The lipid accumulation has a negative effect on atherosclerosis due to the 
propagation of inflammatory cascade. Macrophages can exclude cholesterol, secreting it 
through ATP-binding cassette transporters, such as ABCA1, offering cholesterol to 
ApoA1 to form HDL (Cho et al. 2007; Tall and Yvan-Charvet 2015). Macrophage 
scavenge receptors (MSR-A or CD204) internalize oxLDL in an unregulated manner 
(Kelley et al. 2014) and have been over expressed in lesional macrophages. A subcellular 
accumulation of iron ions caused overproduction of intracellular reactive oxygen species 
(ROS), leading to down-regulation of cholesterol efflux pump, ABCA1. In contrast, 
MSR-A was up-regulated due to the generation of ROS at the subcellular level (Hao et al. 
2015). The outcomes of these previous studies warrant that scavenging ROS via MSR-
targeting and up-regulation of ABCA1 would serve as an efficient means against plague 
progression. 
It has been reported that amphiphilic nanoparticles were uptaken by macrophages 
through MSR-A, indicating that nanomedicines (NMs) aimed for high affinity binding to 
MSR-A can be utilized as a competitive inhibitor of oxLDL uptake and additionally 
explored to prevent atherosclerotic plaque (Schiener et al. 2014). Therefore, new 
bioactive molecules having a diagnostic property that can regulate the uptake of oxLDL 
and scavenge ROS via interaction with MSR-A will be explored as a pharmacological 
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tool to prevent atherosclerotic plaque progression. 
The emergence of integrated technologies has offered a great deal of theranostic 
resources for site-specific delivery of targeted intervention and diagnosis of the disease 
progress (Jain 2005; Grodzinski, Silver, and Molnar 2006; Prados et al. 2014). Recently, 
graphene quantum dots (GQDs) and nano-graphene have received an enhanced attention 
from various biomedical fields specialized in photo-thermal therapy, tissue engineering 
and drug delivery systems (Peterson et al. 2014; Wang et al. 2014; Raucci et al. 2016; Oh 
and Lee 2015). However, the potential usage of GQDs as a theranostic carrier for 
coronary artery disease (CAD) has been rarely investigated. The ability to scavenge ROS 
in inflamed macrophages with imaging property is highly desirable, as it may allow for 
visualizing multiple molecular processes and overcoming the biological complexity and 
therapeutic difficulties in atherosclerotic plaque targeting. 
This related framework has been involved with the mechanistic regulation of the 
expression of intracellular ROS. To this end, we have developed and evaluated SH-GQDs 
as a theranostic carrier using the pyrolysis process at varying resident time and 
hydrothermal conditions. The morphological analysis based on transmission electron 
microscopy (TEM) and elemental analysis based on energy dispersive spectroscopy 
(EDX) were performed to characterize SH-GQDs. We further evaluated SH-GQDs to 
determine whether or not they can scavenge overproduced ROS in inflamed macrophages 
and stimulate the efflux of oxLDL mediated through over expressed ABCA1.  
The image profiles were also evaluated to define the activation rate elicited in 
MSR-A in mouse macrophage cell line (Raw264.7) that has readily taken up oxLDL, 
thus forming foam cells. The monocytes, such as human THP-1, human monocytes-
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derived macrophages and bone marrow-derived macrophages, need to be differentiated 
into macrophage lineages against external stimuli including inflammatory cytokines and 
ROS associated with oxLDL. Therefore, Raw264.7 cell is a rationale choice to 
investigate the efficacy of SH-GQDs on the regulation of surface receptors, such as 
CD204 and ABCA1.  
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4.2. Materials and Methods 
Materials 
Reduced-glutathione (GSH), citric acid, iron (II) sulfate (FeSO4), terephthalic 
acid (TPA), tetramethylbenzidine (TMB), horseradish peroxidase (HRP), dichloro-
fluorescence diacetate (DCFDA) and dextran sulfate were purchased from Sigma-Aldrich 
(St. Louis, MO). Mouse macrophage cell line (Raw264.7), Dulbecco’s modified eagle’s 
medium (DMEM) (30-2601) and penicillin-streptomycin solution (30-2300) were 
purchased from ATCC (Manassas, VA). Fetal bovine serum (FBS) was purchased from 
Atlantic biological (Atlanta, GA). All other reagents and solvents were of analytical 
grade. 
 
Preparation of Thiolated-Graphene Quantum Dots (SH-GQDs) 
SH-GQDs were prepared by thermal treatment of carbon source (citric acid) in 
the presence of a surface modifier (reduced-glutathione, GSH). Briefly, citric acid (20% 
(w/v)) and varying amount of GSH (0, 7, 14 and 20% (w/v)) were dissolved in deionized 
(DI) water.  Then, 250 µl of solution was transferred into pre-heated glass vial placed in 
the oil bath (equilibrated at 150 °C) (OD=1.3 cm, Screw thread with rubber lined cap, 
Fisher, Pittsburgh, PA). To optimize the properties of SH-GQDs, the vial was applied 
with the thermal treatment for predetermined periods of time (3, 6, 9, 12 and 15 min). It 
was reported that the experimental parameters, such as passivation time and GSH 
concentration, have an integral role in formation of SH-GQDs (Peterson et al., 2014). 
After the synthesis process, the black thick film layer was reconstituted with H2O, and 
then pH was adjusted to 7.4 using 1 M of NaOH or HCl. The solution was further 
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dialyzed to remove free citric acid and GSH using a dialysis bag (3500 MWCO, 
BioDesign, Carmel, NY). GQDs (i.e., a control) were prepared with the same method as 
used for the preparation of SH-GQDs except the presence of GSH in citric acid solution.   
 
Characterizations of SH-GQDs 
The UV-vis spectra of SH-GQDs were examined at room temperature (RT) using 
Spectronic 20D (ThermoScientific, Waltham, MA). For fluorescence (FL) measurement 
of the quantum yields (QYs), the excitation and emission spectra of SH-GQDs solutions 
were examined using a Cary Eclipse fluorescence spectrophotometer (Varian Inc., Palo 
Alto, CA) with Xe lamp as an excitation source.   
For the calculation of QYs, the integrated emission spectra of SH-GQDs were 
assessed based on a quinine hydrochloride solution prepared in 0.1 N H2SO4 (ϕ = 0.55) 
which was used as a reference. The following equation was used: ϕ2 = ϕ1 × (I2/I1) × 
(A1/A2) × (n21/n22), where ϕ stands for the quantum yield, I represents the integrated 
fluorescence intensity, A is the absorbance, n is solvent refractive index (n1 = 1.33 for 0.1 
N H2SO4 and n2 = 1.33 for water) and the subscripts 1 and 2 denote the values for the 
quinine hydrochloride solution and SH-GQDs, respectively (Chandra et al. 2013; Zhuang 
et al. 2003). Transmission electron microscopy (TEM) and Energy-Dispersive X-ray 
Spectroscopy (EDS) were conducted using TEM CM12 (FEI, Hillsboro, OR) at 80 kV 
accelerating voltage and scanning electron microscopy (ESEM, XL 30, Hillsboro, OR) 
equipped with EDAX analytical capabilities including elemental analysis. To determine 
the concentration of thiol (-SH) present in SH-GQDs, the Ellman’s assay was performed 
(Jindal, Wasnik, and Nair 2010). 
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Effects of SH-GQDs on Radical Scavenging 
Radical scavenging efficacy of SH-GQDs in the presence of hydroxyl radicals 
was evaluated based on horseradish peroxidase (HRP)-coupled reactions assessed by 
spectrophotometric detection of absorbance at 650 nm (Song et al. 2010) using a 
Spectronic 20D (ThermoScientific, Waltham, MA). The samples (100 µg/ml) of GQDs 
or SH-GQDs in 1 ml phosphate buffer saline solution (10 mM of PBS, pH=7.4) 
containing 50 or 300 µM H2O2 were used to produce the reaction process at 37 °C for 15 
min, and then the reactants were mixed with 200 µM TMB and 0.1 U/ml of HRP. The 
absorbance values were spectrophotometrically monitored at 650 nm. 
For the validation process on scavenging efficacy of SH-GQDs, terephthalic acid 
(TPA) was used as a fluorescence probe. TPA could capture •OH and transform into 2-
hydroxy terephthalic acid (λex: 315 nm and λem: 430 nm), and thus has been used to 
determine the concentration of •OH (Sun et al. 2014). Briefly, 100 µg/ml GQDs or SH-
GQDs in PBS (pH=7.4) were incubated with 300 µM H2O2 at 37 °C for 30 min. To this 
solution, TPA solution containing 0.2 mM FeSO4 (i.e., a catalyst of the oxidation process 
of hydroxyl radicals) was added, and then the fluorescence intensities were examined at 
λex: 315 nm and λem: 430 nm using Cary Eclipse fluorescence spectrophotometer 
(Varian Inc., Palo Alto, CA). The intrinsic photophysical properties of SH-GQDs were 
assessed using Ellman’s assay at the absorbance level of 412 nm and TPA assay at the 
fluorescence level of 430 nm. 
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Cell Viability Study on Raw264.7  
Mouse macrophage cells (Raw 264.7) (TIB-71, ATCC, Manassas, VA) were 
grown in Dulbecco's modiﬁed Eagle's medium (DMEM) supplemented with 10% of fetal 
bovine serum (FBS) (Atlanta Biologicals, Flowery Branch, GA). The media was 
additionally supplemented with 100 units/ml penicillin and 100 µg/ml streptomycin. 
Cells were incubated under the standard culture conditions (37 °C and 5% of CO2).  
To examine potential cytotoxicity of SH-GQDs, the resazurin assay was 
performed on Raw264.7 cells upon being incubated with the varying concentrations of 
SH-GQDs. Briefly, Raw264.7 cells (2x104/well in 200 µl) were placed in a 96-well plate 
and incubated for overnight. Cells were treated with varying concentrations of SH-GQDs 
(0.001, 0.01, 0.05, 0.1, 0.5, 1, 2, 4 and 8 mg/ml) and incubated for 24 hr. The resazurin 
solution was added into the wells according to the company’s description (Promega, 
Madison, WI). The fluorescence intensities after the incubation for 4 hr were examined 
using the multimode detector (λex: 560 nm and λem: 590 nm) (DTX 880, Beckman 
Coulter, Indianapolis, IN).   
 
Apoptosis Assay with Annexin V/Propidium Iodide 
For accurate assessment of cell death, Annexin V/Propidium Iodide (PI) apoptosis 
assay was performed to quantify the numbers of apoptotic cells (Cayman Chemical 
Company, Ann Arbor, MI). After Raw264.7 cells were treated with varying 
concentrations of SH-GQDs, cells were washed twice with PBS and stained with 
Annexin V and PI for 10 min at room temperature. The levels of live, early/late apoptosis 
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and necrosis were determined using BD FACS Canto II flow cytometer equipped with 
BD FACS Diva software (BD Biosciences, San Jose, CA).  
 
Effects of SH-GQDs on oxLDL and ROS Production  
The amount of intracellular ROS was determined using the same method as 
previously described (Oh and Lee 2014). Raw264.7 cells were treated with varying 
concentrations of oxLDL (human medium oxidized low density lipoprotein, 0.5, 1 and 2 
µg/ml) (Kalen Biomdeical, LLC, Montgomery Village, MD) in the presence or absence 
of SH-GQDs (1, 10 and 20 µg/ml). After the incubation for 24 hr, Raw264.7 cells were 
stained with peroxide-sensitive fluorescent dye (2',7'–dichlorofluorescin diacetate, 
DCFDA) and the fluorescent intensities were assessed using a multimode detector (λex: 
485 nm and λem: 515 nm) (DTX 880, Beckman Coulter, Indianapolis, IN).  For cell 
viability measurement against oxLDL, the resazurin solution was added into the wells 
and then the fluorescent intensities were determined using the same method as previously 
described.  
 
Effects of SH-GQDS on Inhibition of ox-LDL Uptake 
The efficacy of SH-GQDs on inhibition of DiO-oxLDL (2 µg/ml) (human DiO-
medium oxidized LDL (DiO, 3,3'-dioctadecyl-oxacarbocyanine, ex: 485 nm; em: 515 
nm) (Kalen Biomdeical, LLC, Montgomery Village, MD) uptake by Raw264.7 cells was 
evaluated based on mean fluorescence intensity. In brief, cells were treated with DiO-
oxLDL with or without SH-GQDs in DMEM (1, 10, 20 and 50 µg/ml) for 24 hr. Cells 
were collected and resuspended in flow cytometry buffer, and then the DiO mean 
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fluorescence intensity of intact single cells was quantitated. The obtained data were 
background subtracted and the amount of oxLDL uptake was normalized as the 
percentage oxLDL uptake amount as compared to mean fluorescence intensity of oxLDL 
only (i.e. control group).  
For confocal microscopy, cells were fixed with 2% paraformaldehyde for 10 min 
and counterstained with DAPI (300 nM) (Life Technologies, Grand Island, NY) before 
being imaged using Leica TCS SP5 II confocal microscopy. The obtained images were 
characterized using ImageJ.  
 
Statistical Analysis 
Data were presented as a mean ± standard deviation (S.D.). One-way ANOVA 
was used to compare the means of independent samples. F-ratio was calculated using 
SPSS software (SPSS, Chicago, IL) and Tukey’s HSD was used for a post-hoc analysis. 
P-values of less than 0.05 were considered as statistically significant. All experiments 
were conducted in triplicate unless otherwise specified. 
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4.3. Results and Discussions 
Synthesis and Properties of Thiolated-Graphene Quantum Dots (SH-GQDs) 
Thiolated-graphene quantum dots (SH-GQDs) were prepared by directly 
pyrolyzing citric acid (CA) along with a surface modifier (reduced glutathione, GSH) 
(Figure 25) under varying hydrothermal conditions. The color of the solution was turned 
into dark brown upon carbonization. It showed strong luminescence property under UV 
light (365 nm). It was previously reported that the condensation products of citric acid 
amides were the main molecular structures contributed to the luminescence of the GQDs 
(Ogi et al. 2014).  
The UV-vis absorption spectra, fluorescent excitation (FLE) and emission bands 
of SH-GQDs (FL) in aqueous solution are shown in Figure 26. The peak of bright violet-
blue fluorescent emission band was displayed upon excitation of SH-GQDs solution at 
350 nm. There are two distinct UV/vis absorption peaks appeared at 240 and 350 nm. 
The absorption band at 240 nm is attributed to the π→π* transition of the aromatic sp2 
domains, subsequently resulted in fluorescent signal loss (Dong et al. 2013). The SH-
GQDs solution (10 µg/ml) at room temperature displayed a homogenous phase without 
any apparent precipitation and exhibited strong violet-blue luminescence at 350 nm under 
ultraviolet light (the inset image of Figure 26).  
When SH-GQDs solution was excited, the peak of bright violet-blue fluorescent 
emission band was shifted from 350 to 440 nm. The quantum yields (QYs) of SH-GQDs 
were calculated based on quinine hydrochloride dissolved in 0.1 N H2SO4 as a reference 
(ϕ = 0.55) (Figure 27). The residence time of the pyrolysis cycle and an addition of 
varying amounts of GSH greatly affected the values of QYs. The QY of GQDs prepared 
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in the absence of GSH excited at 350 nm is calculated to be 3%. However, the QYs of 
SH-GQDs in the presence of varying ratios of GSH significantly increased (43±3.2% for 
1:1 ratio). SH-GQDs thermally pyrolyzed in the presence of GSH (1:1 ratio) for 15 min 
displayed a strong fluorescent emission band indicative of complete surface passivation 
with the surface co-doped nitrogen and sulfur atoms, which is in a close agreement with 
the previous reports (Dong et al. 2013; Zhang, Gao, and Li 2014).  
The fluorescence source of SH-GQDs was considered to be due to the radiative 
excitation recombination at the surface of the formulations (Liu et al. 2012). The 
radiative recombination of band-edge excitons affects the photoluminescence quantum 
yields (QYs) of SH-GQDS, which are determined through the hypothetical model that 
link the surface ligands offered from the surface modifier with specific chemical 
components to the rate constants for non-radiative exciton decay (Peterson et al. 2014). It 
has been reported that carbon-based quantum dots co-doped with nitrogen and sulfur had 
high-quantum yields (QYs) (Dong et al. 2013; Zhuo et al. 2015; Qu et al. 2013). It was 
previously demonstrated that carbon dots synthesized by a facile one-step approach using 
citric acid and glutathione showed high-QY (about 80%) (Zhuo et al. 2015). SH-GQDs 
synthesized in our study under mild reaction temperature (150 °C) had QY around 43%, 
which was closely matched with the outcomes of carbon dots, when they were 
synthesized under such conditions as molar ratio of precursors (1:1 of CA:GSH), 
incubation time (10 min) and reaction temperature (200 °C) (Zhuo et al. 2015).  
The size of SH-GQDs was investigated using both TEM and dynamic light 
scattering (DLS) methods (Figure 28). The average size of SH-GQDs measured by DLS 
was around 9 nm, which was in a close agreement with previous report (Qu et al. 2013), 
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whereas the average size of SH-GQDs from TEM image assay was 21.3±5.2 nm. It could 
be possible that TEM analysis with low-resolution images has limited accuracy in 
assessment of the size of small nano-molecules like SH-GQDs. To examine the size of 
quantum dots, TEM with high resolution property (i.e. HR-TEM) or atomic force 
microscopy (AFM) analysis should be utilized. It has been reported that amphiphilic 
nanoparticles having a size around 160 nm localized to plaque lesions (Lewis et al. 2015). 
Thus, SH-GQDs with a size of 21.3±5.2 nm were small enough to penetrate into plaque 
lesions and produce beneficial effects on pathological conditions.  
The elemental analysis indicated that SH-GQDs are mainly composed of carbon, 
nitrogen, oxygen and sulfur (Figure 29). However, GQDs without GSH had only two 
distinct peaks for carbon and oxygen, suggesting that hydrothermal pyrolysis cycle of CA 
in the presence of GSH constrained the composition and reshaped the surface properties 
of SH-GQDs, and subsequently affected the QYs of SH-GQDs. 
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Figure 25. The scheme for the synthesis process of thiolated-GQDs which were 
hydrothermally prepared using citric acid as a carbon source in the presence of 
glutathione.  
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Figure 26. Characterization of SH-GQDs. UV-vis absorption spectra and fluorescence 
(FL) spectra of SH-GQDs. Inset: Photograph of the obtained SH-GQDs under white light 
(left) and ultraviolet (UV) light at 350 nm (right).  
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Figure 27. Effects of the GSH mass in the precursor (citric acid) and reaction time on the 
FL quantum yields (QYs) of the obtained SH-GQDs.  
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Figure 28. TEM images of SH-GQDs (1:1 ratio of GSH with reaction time for 15 min). 
Inset: Frequency histogram of SH-GQDs. The size of SH-GQDs ranged from 10 to 30 
nm with an average size of 21.3±5.2 nm.  
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Figure 29. EDX spectra of GQDs and SH-GQDs.  
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Characterization of SH-GQDs 
The fluorescence emission spectrum of SH-GQDs prepared with varying ratios of 
the surface modifiers (i.e., GSH) at different residence periods of the pyrolysis cycle was 
examined. As shown in Figure 30 and 31, the FL emission profiles for all the solutions 
prepared under varying synthesis conditions were obtained at the same absorbance levels. 
The insets in Figure 30 and 31 showed the absorbance spectra of formulations prepared 
under varying conditions. SH-GQDs prepared with the high ratios of GSH and excited at 
350 nm had strong fluorescent intensity attributed to the changes in UV/Vis spectra of 
SH-GQDs (Inset graph of UV/vis spectra in Figure 30). Similarly, the strong fluorescent 
intensity was observed from SH-GQDs prepared with a longer residence period of the 
pyrolysis cycle (Figure 31).  
The strong absorption peak at 350 nm appeared, because a longer residence 
period of pyrolysis cycle allows for the excitation of multiple surface waves triggered by 
the interaction between a one-dimensional photonic crystal and a metal in the grating 
coupled arrangement. It was evident that SH-GQDs need an effective precursor and a 
proper reaction time to exert superb luminescent properties.  The results of this study 
supported that SH-GQDs with high QYs is closely correlated with the amount of GSH 
and the residence periods of the pyrolysis cycle during the synthesis process.  
The color changes in a series of SH-GQDs solutions (1 mg/ml) prepared at 
varying residence periods of pyrolysis cycle (3 min to 15 min) were clearly shown in 
Figure 32 (Left) in which SH-GQDs solutions (50 µg/ml) displayed distinctive emitted 
luminescence upon exposure to the illumination of UV light (λex: 365 nm) (Figure 32, 
Right).  Even though the excitation wavelength was changed from 275 to 350 nm, the 
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emission spectra of SH-GQDs remain constant independent of the excitation wavelength 
(Figure 33), which could be attributed to the passivated layer of SH-GQDs. The 
maximum excitation and emission wavelength of SH-GQDs were 350 and 440 nm, 
respectively, which was in a close agreement with the absorbance spectrum.  
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Figure 30. Optical Characterization of SH-GQDs. Fluorescence spectra of the aqueous 
solution of SH-GQDs with varying ratios of GSH in the precursor solution (λex=350 nm 
and λem=440 nm). Inset: UV-vis absorption spectra of the obtained formulation with 
varying ratios of GSH.  
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Figure 31. Fluorescence spectra of the aqueous solution of SH-GQDs with varying 
reaction time (λex=350 nm and λem=440 nm). Inset: UV-vis absorption spectra of the 
obtained formulation with varying reaction time.  
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Figure 32. (Left) Photographs of the obtained SH-GQDs with varying reaction time (1 
mg/ml of SH-GQDs in PBS). (Right) Photographs of the obtained SH-GQDs (50 µg/ml) 
under the illumination of UV light at 365 nm.  
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Figure 33. Fluorescence spectra of the SH-GQDs with excitation of different wavelength 
(from 275 to 350 with 15 nm inclement).  
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Anti-Oxidant Effects of SH-GQDs  
Thiol-based compounds, such as glutathione (GSH), cysteine and N-acetyl 
cysteine (NAC), play an integral role in protecting cells from oxidative stress through 
potent antioxidant activities. The total antioxidant capacity of individual thiols was 
determined by the Ellman’s assay that assessed low-molecular mass thiols including 
glutathione in both pure solutions and biological samples (Figure 34 and 35) (Gungor et 
al. 2011; Riener, Kada, and Gruber 2002). As the concentration of SH-GQDs increased, -
SH concentration in SH-GQDs also increased (n=6).  However, thiol groups in SH-GQDs 
were not any more detectable by Ellman’s assay upon exposure to H2O2 (Figure 35), 
which indicates that there were no more free thiol group available for the reaction with 
the reagent to form a thiol-reagent adduct.  
To further investigate whether or not thiol groups are able to scavenge hydroxyl 
radicals, both TMB and TPA assays were performed. In the absence of horseradish 
peroxidase (HRP), no substantial absorbance was displayed at 650 nm, whereas in the 
presence of HRP, the high absorbance readings were displayed at both HRP 
concentrations of 50 and 300 µM (Figure 36). For the groups with SH-GQDs treatments, 
the absorbance value at 650 nm were significantly reduced, indicating that H2O2 is 
scavenged by thiol groups present in graphene quantum dots.  
 
The Fenton reaction was mediated by the reagent solution that is consisted of 
hydrogen peroxide with ferrous iron as a catalyst (Fenton 1894). As the Fenton reaction 
was involved with the oxidation process of hydroxyl radicals in biologicals and the 
creation of free radicals by chemicals, the high fluorescent intensities were observed from 
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those having PBS and GQDs (Figure 37). In the absence of F2SO4, H2O2 did not convert 
into the hydroxyl radicals. The intensity of the solution containing SH-GQDs is 
significantly lower than that of GQDs, indicating that SH-GQDs efficiently removed 
hydroxyl radicals. It can be concluded that SH-GQDs have a high anti-oxidant capacity 
due to the thiol groups present in graphene quantum dots that can scavenge hydrogen 
peroxide and hydroxyl radicals, subsequently demonstrating its potential to prevent ROS 
production at the subcellular level. 
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Figure 34. Radical scavenging efficacy of SH-GQDs. Schematic representation of 
scavenging capacity of thiol present in GQDs.  
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Figure 35. Measurement of thiol concentration of varying concentration of SH-GQDs in 
the presence or absence of H2O2 by Ellman’s assay (** indicates statistically significant 
difference between SH-GQDs with or without H2O2 treatment. p<0.01, n=6).  
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Figure 36. Bar graphs of TMB reaction. Data represented the absorbance at 650 nm in the 
absence or presence of HRP with such treatment groups as PBS, GQDs and SH-GQDs 
(**indicates statistically significant differences between PBS, GQDs and SH-GQDs. 
p<0.01, n=3). 
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Figure 37. Bar graphs of ΔFL intensity demonstrated the anti-oxidant effect of SH-
GQDs. (**indicates statistically significant differences between PBS, GQDs and SH-
GQDs. p<0.01, n=3) 
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Effects of SH-GQDs on Cell viability 
The potential cytotoxicity of SH-GQDs should be thoroughly investigated before 
being further applied as nanocarrier for exogenous compounds. To this end, we examined 
the biocompatibility of SH-GQDs on Raw264.7 cell line using the resazurin assay. SH-
GQDs at the concentrations up to 1 mg/ml appeared to cause about 10 to 20% of cell 
apoptosis after incubation for 24 hr (Figure 38 (A)). However, more than 40% cells were 
dead upon being treated with the concentration of 5 mg/ml. For the concentration of 10 
mg/ml treatment, cells were completely depleted (i.e., apoptosis).  
The extent of necrosis and apoptosis in Raw264.7 induced by SH-GQDs was 
examined using Annexin V/PI staining technique. A flow cytometry analysis on cells 
stained with Annexin V/PI enables to differentiate live and dead cell populations (Q1: 
Early apoptosis, Q2: Late apoptosis, Q3: Live and Q4: Necrosis) (Figure 38 (B)). The dot 
plot for Annexin V and PI staining indicated that the treatment of cells with SH-GQDs at 
the concentrations up to 0.1 mg/ml had almost 100% live cells. Based on the results from 
the resazurin assay and Annexin V/PI staining technique, SH-GQDs at the concentration 
up to 0.1 mg/ml were selected for the further studies.  
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Figure 38. (A) Cell viability study conducted using Resazurin Assay (n=5). (B) Bivariate 
Annexin-V/PI analysis of Raw264.7 cells after 24 hr incubation of SH-GQDs. Q1: the 
cells in early apoptosis; Q2: the dead/apoptotic cells; Q3: the live cells and Q4: Necrosis. 
y-axis indicates Annexin-V, whereas x-axis indicates PI (n=3).  
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Effects of SH-GQDs against oxLDL-induced Cell Apoptosis 
The main features of atherosclerosis include 1) the uptake of oxLDL via MSR-A, 
2) the ensuing overproduction of oxidative stress in plaque macrophages, and 3) the 
subsequent narrowing of the artery due to foam cell disruption (Méndez-Barbero et al. 
2013). The oxidative modification of apolipoproteins activates the vascular endothelium 
and triggers an entry of monocytes to the vascular intima, differentiating into 
phagocytose oxidized LDL (oxLDL) and macrophages (Hansson and Hermansson 2011).  
As shown in Figure 39, the extent of the cell apoptosis was dependent on the 
oxLDL concentration. The effects of SH-GQDs on cell viability mediated by oxLDL (10 
µg/ml) was evaluated after cells were incubated for 24 hr. The incubation period of 24 hr 
is enough to exert cell apoptosis on macrophages against oxLDL. SH-GQDs significantly 
alleviated the cytotoxic effect of oxLDL on macrophages as compared with the negative 
control (p<0.01, n=5). 
To evaluate the dose dependent effects of SH-GQDs on oxLDL induced cell 
viability, varying concentrations of SH-GQDs (1, 10 and 20 µg/ml) were added to the 
cells in the presence of oxLDL (5 and 10 µg/ml) (Figure 40). SH-GQDs recovered the 
viability of Raw264.7 cells against oxLDL (10 µg/ml oxLDL) induced apoptosis (Media: 
65.5±8.1%, 10 µg/ml SH-GQDs: 103.7±4.1% and 20 µg/ml SH-GQDs: 103.4±5.3%). 
These results suggest that the binding of oxLDL to MSR-A in Raw264.7 cells initiates an 
OxLDL-specific signaling event, which leads to apoptosis of macrophages. The results of 
this study validate a novel role of SH-GQDs in macrophage biology with likely 
consequences for the development of an inhibitory strategy against atherosclerotic 
lesions.  
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Figure 39. Cell viability study against varying concentrations of oxLDL (1, 2, 5 and 10 
µg/ml) (** indicates statistically significant difference between negative and oxLDL (10 
µg/ml, p<0.01, n=5).  
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Figure 40. The protective role of SH-GQDs in Raw264.7 cells against oxLDL treatments 
(5 and 10 µg/ml) (** indicates statistically significant difference as compared to the 
media group, p<0.01, n=5). 
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Effects of SH-GQDs against oxLDL-induced ROS 
It was previously reported that oxLDL uptake could lead to the initial toxic effect 
through a progressive enhancement of reactive oxygen species (ROSs) production at the 
subcellular level and a significant depletion of glutathione (GSH) (Giovannini et al. 
2008).  A specific ROS-sensitive dye (DCFDA) was chosen to elucidate the amount of 
ROS generated from an influx of oxLDL (Figure 41). It was found that fluorescent 
intensity of cells exposed to oxLDL varied depending on the oxLDL concentrations (The 
control: 100±14.5%; 1 µg/ml: 204±44.2%; and 2 µg/ml: 247±25.3%). The ROS level was 
lowered as the cells pretreated with oxLDL (2 µg/ml) were co-incubated with varying 
concentrations of SH-GQDs (DCF=143.1±14.2% for 20 µg/ml of SH-GQDs). The 
fluorescent intensity of cells exposed to SH-GQDs (20 µg/ml) was not as strong as that to 
the negative control, indicating that SH-GQDs prevent cells from producing ROS via 
high anti-oxidant capacity stemmed from the thiol groups that can scavenge hydrogen 
peroxide and hydroxyl radicals at the subcellular level. 
To visualize the ROS level at the subcellular region, cells were stained with 
DCFDA dye upon being treated with various conditions including 1) the control, 2) 
oxLDL exposure in the presence of GQDs, and 3) oxLDL exposure in the presence of 
SH-GQDs (Figure 42).  For oxLDL treatment group (in the middle of the images), the 
bright green signals were distinctively displayed as compared with the control group (the 
left image), whereas oxLDL treatment in the presence of SH-GQDs had no green signals 
(the right image). These results indicated that the cellular uptake of oxLDL via MSR-A is 
its concentration dependent and SH-GQDs prevented the uptake of oxLDL. SH-GQDs 
seem to play a protective role against oxLDL-induced ROS at the subcellular level.   
	 107 
 
Figure 41. DCF fluorescence staining of Raw264.7 cells with varying treatments, such as 
different concentrations of oxLDL in the presence or absence of SH-GQDs (** indicates 
statistically significant difference as compared to control group, p<0.01, n=5).  
 
 
	 108 
 
Figure 42. DCF fluorescence images were captured to visualize the subcellular ROS level.  
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The Mechanism behind SH-GQDs Action against oxLDL uptake in Macrophages  
To elucidate the mechanism of SH-GQDs against oxLDL uptake in macrophages 
in vitro, the subsequent study on the relationship between oxLDL and SH-GQDs was 
conducted. It was hypothesized that SH-GQDs bind to MSR-A in competition with 
oxLDL, preventing the cellular accumulation of oxLDL. Confocal microscopy images 
demonstrated that oxLDL (FITC-labeled oxLDL, DiO-oxLDL) was accumulated in the 
cellular region after incubation for 24 hr (Figure 43). In contrast, as cells were co-
incubated with SH-GQDs, green fluorescence signals were significantly reduced.  
To further elucidate the subcellular accumulation profiles of oxLDL, the changes 
in mean fluorescence intensity were examined using a flow cytometry analysis (Figure 
44). It was found that oxLDL up to 2 µg/ml was uptaken by macrophages in a 
concentration-dependent manner. The study on inhibitory effects of SH-GQDs on the 
oxLDL uptake profiles by macrophages showed that the histogram for oxLDL in the 
presence of SH-GQDs was shifted to the left (lower mean fluorescence intensity) (Figure 
45). Moreover, SH-GQDs (1 µg/ml) effectively prevented the uptake of oxLDL as 
compared to GQDs.  
As the concentration of SH-GQDs increased, the inhibition rate of the oxLDL 
uptake by macrophage linearly increased. It was agreed with the previous report that the 
cellular GSH levels and GSH/GSSG status regulated the cellular uptake of oxLDL (Yang 
et al. 2015). These results suggested that SH-GQDs are capable of inhibiting oxLDL 
uptake by macrophages, demonstrating an essential inhibitory property of the GSH-
including antioxidant system against atherosclerosis. 
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Figure 43. Confocal microscopy analysis of oxLDL uptake by Raw264.7 cells. White 
arrows indicate strong green signals exerted by DiO-oxLDL uptake inside Raw264.7 
cells (Scale bars=50 µm).  
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Figure 44. (Left) Flow cytometry histogram illustrating cellular uptake of DiO-oxLDL. 
Inset: Histogram showed a peak-shifted to right as DiO-oxLDL concentration increased 
(0.4±0.1% to 99.4±0.1%) (n=3). (Right)  Flow cytometry cellular uptake assay of DiO-
oxLDL (n=3). Raw264.7 cells were incubated with varying concentration of DiO-oxLDL 
(0.2, 0.5, 1 and 2 µg/ml) for 24 hr at 37 °C (n=3). 
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Figure 45. (Left) Flow cytometry histogram illustrating cellular uptake of DiO-oxLDL (2 
µg/ml) in the presence of SH-GQDs (50 µg/ml). Inset: Histogram showed a peak-shifted 
to left as SH-GQDs presented. (Right) Percentages of oxLDL (2 µg/ml) uptake with or 
without varying concentrations of GQDs and SH-GQDs (1, 10, 20 and 50 µg/ml) (n=3).    
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Effect of SH-GQDs on ABCA1 and MSR-A Expressions 
The major protein group of high-density lipoproteins (HDL) interacts with 
macrophages to induce the efflux of excess cholesterol via ABCA1 (i.e., specific 
transporters of the ATP binding cassette (ABC) gene family) (Wang et al. 2004). In 
atherosclerosis, there is a deregulation process of cholesterol uptake and efflux transport 
by macrophages. oxLDL, which is a major source of cholesterol, contributes to the down-
regulation of cholesterol efflux and up-regulation of expression of scavenger receptors, 
especially MSR-A (or CD204) (Chistiakov, Bobryshev, and Orekhov 2016). 
As the removal of oxLDL helps to protect against the formation of macrophage 
foam cells, the effects of oxLDL or SH-GQDs on the regulation of ABCA1 were 
examined by flow cytometry technique. The expressions of ABCA1 in macrophages 
treated with either LDL or oxLDL decreased as compared to the media control (the 
negative control: 100±7.6%; LDL: 82.7±1.2%; and oxLDL: 79.2±1.7%) (Figure 46). The 
level of ABCA1 expression increased upon being incubated with GQDs or SH-GQDs 
(GQDs: 92.8±0.5% and SH-GQDs: 101.5±3.1%), whereas cells treated with SH-GQDs 
showed higher ABCA1 levels than those with GQDs.   
The expression of CD204 on the surface of macrophages reside at atherosclerotic 
plaque is essential for the uptake of oxLDL (Tarhda et al. 2013). It will eventually form 
foam cells and progress into lipid-laden plaque. To examine the extent of SH-GQDs to 
alleviate MSR-A expression on the surface of macrophages, the levels of MSR-A were 
evaluated after the treatment with various groups described in Figure 47. The level of 
MSR-A on the surface of macrophages decreased upon being treated with SH-GQDs as 
compared to those with oxLDL (oxLDL: 112.1±8.8% and SH-GQDs: 91.5±4.2%).  
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Figure 46. ABCA1 expression in Raw264.7 cells upon being treated with various 
conditions (2 µg/ml LDL, 2 µg/ml oxLDL, oxLDL+GQDs (50 µg/ml) and oxLDL+SH-
GQDs (50 µg/ml)) measured by flow cytometry after specific staining of ABCA1 (** 
indicates statistically significant difference between oxLDL and SH-GQDs, n=3, p<0.01).   
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Figure 47. CD204 expression in Raw264.7 cells upon being treated with various 
conditions (2 µg/ml LDL, 2 µg/ml oxLDL, oxLDL+GQDs (50 µg/ml) and oxLDL+SH-
GQDs (50 µg/ml)) measured by flow cytometry after specific staining of CD204 (** 
indicates statistically significant difference between oxLDL and SH-GQDs, n=3, p<0.01).   
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Immunocytofluorescence (ICF) image analysis 
ICF analysis was performed to visualize the expression of CD204 after such 
treatments as the negative control, oxLDL treatment and oxLDL treatment in the 
presence of either GQDs or SH-GQDs (Figure 48). For the group of oxLDL treatment, 
red fluorescence from CD204 was clearly displayed. However, when cells incubated with 
oxLDL were simultaneously treated with SH-GQDs, weaker red fluorescence was 
displayed, indicating that SH-GQDs affected the expression of CD204 on macrophages.  
As the expression of CD204 is regulated by various endogenous and exogenous 
compounds including antioxidants, the pro-atherogenic role of oxLDL seems to be 
involved with a process mediated by oxidative damage. Macrophages generally take up 
chemically modified LDLs including oxidized LDL (oxLDL) through the scavenger 
receptor pathway and transform into foam cells. The results of our studies using cultured 
macrophages have revealed the potential atherogenic effects of oxLDL, such as 
enhancement of monocyte adhesion to endothelial cells and induction of macrophage cell 
death. Current studies demonstrated that SH-GQDs efficiently prevented the progression 
of atherosclerotic plaques in vitro. Future study will be designed to test the effects of SH-
GQDs on a physiologically more relevant atherosclerotic environment using in vivo 
models which will verify whether or not SH-GQDs inhibit the differentiation of 
monocytes into macrophage cells against oxLDL.  
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Figure 48. Immunocytofluorescence (ICF) analysis of CD204 expression (in red) with a 
counterstaining of nuclei with DAPI (in blue) (Scale bars=50 µm). 
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4.4. Conclusion 
The relationship among the expression of macrophage scavenger receptor A 
(MSR-A), lipid accumulation and ROS production in macrophages were evaluated to find 
an efficient preventive means against atherosclerosis. The size of thiolated-graphene 
quantum dots (SH-GQDs) prepared by hydrothermal pyrolysis technique ranged from 10 
to 30 nm, and they are mainly composed of carbon, nitrogen, oxygen and sulfur. The 
morphological analysis and elemental analysis confirmed that SH-GQDs can stimulate 
the efflux of oxLDL mediated through over-expressed ABCA1 and scavenge ROS in 
inflamed macrophages. The enhancement of lipid efflux and down-regulation of CD204 
in mouse macrophage cell line (Raw264.7) by SH-GQDs supported its promising usage 
as a theranostic carrier to prevent foam cell formation and subsequent atherosclerotic 
plaque progression.  
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CHAPTER 5 
DEVELOPMENT OF THIOLATED-GRAPHENE QUANTUM DOTS FOR DOWN-
REGULATION OF MACROPHAGE SCAVENGER RECEPTOR: IN VIVO STUDY 
 
5.1. Rationale 
In previous chapter, thiolated-graphene quantum dots (SH-GQDs) were explored 
as a theranostic carrier for endogenous/exogenous compounds against atherosclerosis. 
SH-GQDs prepared by hydrothermal pyrolysis technique were characterized by size 
analysis, morphological analysis and elemental analysis based on energy dispersive 
spectroscopy (EDX).  
It was found that as the concentration of SH-GQDs increased, the inhibition rate 
of the oxLDL uptake by macrophage was linearly increased. The expressions of ABCA1 
in macrophages treated with either LDL or oxLDL decreased as compared to the media 
control (the negative control: 100±7.6%; LDL: 82.7±1.2%; and oxLDL: 79.2±1.7%). The 
level of ABCA1 expression increased as cells were incubated with GQDs or SH-GQDs 
(GQDs: 92.8±0.5% and SH-GQDs: 101.5±3.1%), whereas cells treated with SH-GQDs 
showed higher ABCA1 expression than those with GQDs. The level of CD204 on the 
surface of macrophages decreased upon being treated with SH-GQDs as compared to 
those with oxLDL (oxLDL: 112.1±8.8% and SH-GQDs: 91.5±4.2%). 
Subsequently, in this chapter, the relationship among the production of nitric 
oxide (NO) by endothelial cells and endothelial cell junction against oxLDL treatment 
was established for the elucidation of the mechanisms behind the onset and progress of 
atherosclerosis.  
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Because in vivo zebrafish model has been used as a prognostic model for the 
assessment of potential cytotoxicity of nanomaterials in cardiac development, developing 
a predictive model for cardiotoxicity of nanocarriers using zebrafish embryos and larvae 
was conducted (Duan et al. 2013a; Bakkers 2011; Duan et al. 2013b; Lin, Zhao, and Nel 
2013). Therefore, in vivo evaluation of SH-GQD formulations was performed using 
zebrafish embryos/larvae and their capability to scavenge the ROS production in 
zebrafish larvae against hydrogen peroxide (H2O2) was investigated.  
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5.2. Materials and Methods 
Materials 
Reduced-glutathione (GSH), citric acid, lipopolysaccharides (LPS), sulfanilamide, 
N-1-napthylethylenediamine dihydrochloride, sodium azide and dextran sulfate were 
purchased from Sigma-Aldrich (St. Louis, MO). All other reagents and solvents were of 
analytical grade.  
 
in vitro Cellular Uptake Study 
Raw264.7 cells (3x105/well in 500 µl) were seeded on a 24-well plate and 
incubated for overnight. Cells were treated with varying concentrations of SH-GQDs (10, 
20, 50, 100 and 200 µg/ml) at 37 °C for 24 hr. After the incubation, cells were gently 
washed with the cold PBS solution three times to remove SH-GQDs remained on the 
surface of cells. After washing cells with PBS, cells were scraped and centrifuged to 
collect the cell pellet. Cells were suspended in flow cytometry buffer containing 1% (w/v) 
BSA and 0.1% sodium azide. The cells were analyzed using a BD FACSCanto II flow 
cytometer equipped with BD FACSDiva software (BD Biosciences, San Jose, CA). For 
the time-dependent cellular uptake study, cells were treated with 200 µg/ml of SH-GQDs 
at specific time intervals (0.5, 1, 2, 5, 10 and 24 hr). After the treatment, cells were 
collected and analyzed using the same method as previously described.  
For further investigation of the cellular uptake mechanism and a pathway for SH-
GQDs on Raw264.7 cells, cells were incubated with various conditions, such as low 
temperatures (4 °C), ATP-depleted condition and pre-treatment with dextran sulfate (10 
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µg/ml) in the presence of SH-GQDs (50 µg/ml). For ATP-depleted condition, the cells 
were pre-treated with 50 mM 2-deoxy-D-glucose and 25 mM NaN3 for 1 hr.  
 
oxLDL Efflux by SH-GQDs 
The efficacy of SH-GQDs on DiO-oxLDL efflux (Kalen Biomdeical, LLC, 
Montgomery Village, MD) by Raw264.7 cells was evaluated based on the percent of 
positive cells containing DiO-oxLDL. In brief, cells were treated with DiO-oxLDL (2 
µg/ml) in DMEM for 24 hr. After the incubation, cells were treated with media (positive 
control) and SH-GQDs (50 µg/ml). Cells were collected and suspended in flow cytometry 
buffer, and then the DiO mean fluorescence intensities of intact single cells were 
quantitated. The obtained data were background subtracted and the amount of oxLDL 
uptake was normalized as percentage oxLDL uptake amount as compared to mean 
fluorescence intensity of DMEM treatment (i.e. positive).  
 
Transepithelial Electrical Resistance (TEER) Measurement against oxLDL  
To evaluate TEER of human primary umbilical vein endothelial cells (hUVECs) 
against oxLDL, hUVECs (PCS-100-010), vascular cell basal medium (PCS-100-030) and 
endothelial growth kit–VEGF (VEGF, vascular endothelial growth factor) (PCS-100-041) 
purchased from ATCC (Manassas, VA) were used. The medium was gently mixed with 
growth supplements and kept in the refrigerator at 4°C. hUVECs were cultured under the 
standard cell culture conditions (5% CO2 and humidified air at 37°C). 
As cells were confluent, hUVECs with 5x105 per well were seeded on the apical 
side of inserts (pore size=3 µm and surface area=1.12 cm2) (Corning Costar Transwell, 
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Corning Incorporated, Tewksbury, MA) freshly coated with 50 µg/ml of human 
fibronectin in 12-well plate and cultured for 2 days. The cells were treated with oxLDL 
(10 µg/ml) in the presence of GQDs or SH-GQDs (10 µg/ml) and TEER values were 
measured using the epithelial volt-ohm meter (EVOM) and STX2 electrode (World 
Precision Instruments, Sarasota, FL). Background TEER was subtracted and the final 
resistances were presented as Ω-cm2 (TEER x surface area).  
 
Assessment of the Amount of Nitric Oxide (NO)  
Nitric Oxide (NO) produced through cellular interaction with VEGF was 
quantified using the Griess assay (Oh and Lee 2013a). The Griess reagent was prepared 
by mixing of 0.1% of N-(1-Naphthyl) ethylenediamine dihydrochloride (NED) dissolved 
in DI water and 1% of sulfanilamide dissolved in 5% (v/v) phosphoric acid solution. 
hUVECs with 2x104 per well were seeded on 96-well plate and cultured for 
overnight until cells were fully attached. The cells were treated with varying treatment 
groups such as media, L-NAME (1 mM), oxLDL (10 µg/ml) and oxLDL in presence of 
SH-GQDs (1, 5 and 10 µg/ml). After the incubation for 24 and 48 hr, 100 µl media in the 
plate were transferred to fresh 96-well plate and 1% sulfanilamide solution (50 µl) was 
added to each well and the plate was incubated for 5 min at room temperature. Then, 0.1% 
NED solution (50 µl) was added to each well.  The absorbance was measured at 550 nm 
using the multimode detector and extrapolated to the concentration of NO (µM). 
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in vivo Study  
Zebrafish has been used as a prognostic model for assessment of potential 
cytotoxicity of nanomaterials in cardiovascular disease. The evolving embryo in 
zebrafish is reasonably sensitive to external stimuli and the heart is formed as a first 
organ during the development process of transparent embryos (Duan et al. 2013a; 
Bakkers 2011).  
Zebrafishes (wild-type, wt) were raised in an environmentally controlled facility 
(Water: egg water (0.6 g/L sea salt); Photoperiod: 14 hr light/10 hr dark cycle; and 
Temperature: 28±0.5 °C). For such studies as embryonic mortality, malformation, and 
ROS generation assessment, fertilized eggs were collected and placed in 24-well plates (2 
ml of 30% Danieau’s solution (58 mM NaCl, 0.7 mM KCl, 0.4 mM MgSO4, 0.6 mM 
Ca(NO3)2, 5 mM Hepes, pH 7.4) per well). Fertilized eggs were treated with varying 
concentrations of SH-GQDs (0.02, 0.05, 0.1, 0.2, 0.3, 0.6, 0.8, and 1 mg/ml) for 7 dpf 
(dpf: days-post fertilization). In all experiments, dead embryos and larvae were separated 
from the 24-well plates every 24 hr.  
To assess ROS accumulation in zebrafish larvae, larvae were collected at 48 hpf 
and stained with ROS-sensitive dye (DCFDA) for 30 min. After the incubation, stained 
larvae were transferred to fresh media in 96-well plate and then incubated with varying 
treatment groups such as media, hydrogen peroxide (H2O2, 50 µM) and H2O2 in presence 
of SH-GQDs (25, 100, 200 and 300 µg/ml). The fluorescence was measured with 
multimode detector (DTX 880, Beckman Coulter Inc., CA) at excitation 485 nm and 
emission 515 nm after every 10 min. The spontaneous oxidation of DCFDA was recorded 
in the wells without larvae. H2O2 treatment group was served as a positive control. 
	 125 
Statistical Analysis 
Data were presented as a mean±standard deviation (S.D.). One-way ANOVA was 
used to compare the means of independent samples. F-ratio was determined using SPSS 
software (SPSS, Chicago, IL) and Tukey’s HSD was used for a post-hoc analysis. P-
values of less than 0.05 were considered as statistically significant. All experiments were 
conducted in triplicate unless otherwise specified. 
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5.3. Results and Discussions 
SH-GQDs Uptake with varying concentrations by Macrophages 
The cellular imaging has provided crucial information in assessment of the 
efficacy of the endocytosis process. It was found that SH-GQDs with high quantum 
yields can be utilized to label single-cell biophysics in the absence of any extra 
fluorescent dyes. The subsequent studies are conducted to assess the suitability of SH-
GQDs for theranostic application by elucidating the interaction of SH-GQDs with 
Raw264.7 and the uptake mechanism of SH-GQDs. 
To evaluate the uptake rate of SH-GQDs, the fluorescence values from cells 
treated with varying concentrations of SH-GQDs (10, 20, 50, 100 and 200 µg/ml) were 
examined using a flow cytometry (Figure 49 and 50). As shown in Figure 49, there was a 
dose-dependent increase in mean fluorescence intensity at the concentrations from 10 to 
200 µg/ml. The histogram showed a peak that was shifted to right, as SH-GQDs 
concentration increased (Figure 50).  
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Figure 49. Flow cytometry cellular uptake assay of SH-GQDs (n=3). Raw264.7 cells 
were incubated with varying concentration of SH-GQDs (10, 20, 50, 100 and 200 µg/ml) 
for 24 hr at 37 °C.  
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Figure 50. Flow cytometry histogram illustrating cellular uptake of SH-GQDs. Inset: 
Histogram showed a peak-shifted to right as SH-GQDs concentration increased (7.2±0.1% 
to 49.1±1.5%). 
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SH-GQDs Uptake with varying incubation time by Macrophages 
To determine the parameters of the uptake kinetics, macrophages were incubated 
with 200 µg/ml SH-GQDs for various time intervals (30 min, 1, 2, 6, 10 and 24 hr) 
(Figure 51). The uptake rate of SH-GQDs followed a time-dependent profile. For up to 2 
hr, there was no notable positive cell population observed from the results of a flow 
cytometry study. After the incubation for 10 hr, the significant amount of the cellular 
uptake of the SH-GQDs was observed and the rate substantially increased as a function of 
time (for 24 hr, 49.4±8.8 %).  
 
Inhibition of Cellular Uptake of SH-GQDs on Macrophages 
It has been well established that endocytosis is generally energy-dependent uptake 
process which can be slowed as the cells are incubated at low temperature (4 °C) or under 
the ATP-depleted condition (Shang et al. 2014). To further investigate the uptake 
mechanism of SH-GQDs via MSR-A, the nonspecific class A scavenge-receptor blocking 
agent (0.5 µg/ml dextran sulfate) was selected to reduce the uptake rate of SH-GQDs. 
Particularly, as compared with the medial control, the low mean fluorescence intensity 
levels from cells incubated at 4 °C or under the ATP-depletion condition were observed 
(Figure 52).  When cells were pre-incubated with dextran sulfate, there was a decrease in 
mean fluorescence intensity. Confocal microscopy images of macrophages treated with 
SH-GQDs enhanced the fluorescent levels after the incubation for 24 hr (Figure 53). 
These results clearly demonstrated that SH-GQDs could enter macrophages in an energy-
dependent manner via a MSR-A-mediated endocytosis mechanism.  
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Figure 51. Flow cytometry cellular uptake assay of SH-GQDs (200 µg/ml) with varying 
incubation time (0.5, 1, 2, 5, 10 and 24 hr) (n=3).  
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Figure 52. MFI for SH-GQDs (50 µg/ml) incubated in Raw264.7 cells for 24 hr under 
different conditions, including negative (37 °C), 4 °C, dextran sulfate (scavenger 
receptor-A ligands) and ATP-depletion (50 mM 2-deoxy-D-glucose and 25 mM NaN3) 
(n=3). 
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Figure 53. Bright field images and corresponding confocal microscopy images of Raw 
264.7 cells treated with SH-GQDs (200 µg/ml) at the excitation wavelength of 405 nm 
after incubation for 0.5 and 24 hr (Scale bars=50 µm).  
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Enhancement of oxLDL Efflux by SH-GQDs 
Lipid-laden macrophages form foam cells and gradually evolved into plaque at 
atherosclerotic lesion. Thus, the role of lipoprotein-macrophage interactions in 
atherogenesis has been focused largely on the foam cell (Li and Glass 2002) and the 
enhancement of lipid efflux is an ideal approach to mitigate the progression of plaque. 
The efflux of oxLDL from macrophages was promoted by co-incubation of cells with 
SH-GQDs. The study on the efflux of oxLDL from macrophages found that SH-GQDs 
treatment for 24 hr was effective to induce oxLDL efflux as compared to the media 
control (Control: 72.4±2.4% and SH-GQDs: 39.2±2.2%) (Figure 54 and 55).  
In addition, as shown in Figure 54, the oxLDL efflux profiles mediated by SH-
GQDs increased in a time-dependent manner (Figure 55). As the incubation period 
increased, the exclusion amount of oxLDL increased. There was a significant difference 
in the efflux amount of oxLDL incubated with SH-GQDs between two treatment periods 
(3 hr: 73.9±1.5% and 24 hr: 39.2±2.2%). These results indicated that the enhancement of 
lipid efflux from lipid-laden macrophages by SH-GQDs could be a promising strategy to 
prevent foam cell formation and subsequent atherosclerotic plaque progression.  
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Figure 54. Efflux of oxLDL from Raw264.7 cells after pretreatment with DiO-oxLDL (2 
µg/ml) was investigated using a flow cytometry. Raw264.7 cells were treated with two 
different groups: media control and SH-GQDs (50 µg/ml) (** indicates statistically 
significant difference between positive and SH-GQDs, n=3, p<0.01).  
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Figure 55. oxLDL efflux mediated by SH-GQDs treatment occurred in a time dependent 
manner (n=3).   
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The Measurement of Nitric oxide (NO) Release 
The cellular NO production associated with Raw264.7 activation by 
lipopolysaccharide (LPS) is examined as a pro-inflammatory marker. As NO is involved 
with the contractility and limits the vascular remodeling, NO at the low concentration 
could be utilized as a potential therapeutic option against atherosclerosis. However, the 
protective efficacy of NO becomes less potent, once the excessive amount of NO is 
produced from the macrophage activation process. 
To examine whether or not SH-GQDs trigger an excessive production of NO, 
macrophages were incubated with varying concentrations of SH-GQDs and the amount 
of NO in the supernatant culture medium is quantified using Griess colorimetric assay 
(Figure 56). It was found that the significant amount of NO (21.1±1.3 µM) was produced, 
when cells were treated with LPS (100 ng/ml). The treatment of IL-4, an alternative 
macrophage activator, produced no traceable amount of NO. In addition, SH-GQDs 
treatments at the concentrations up to 0.1 mg/ml didn’t trigger the inflammatory process 
in macrophages.  
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Figure 56. Assessment of nitric oxide (NO) release from Raw264.7 cells using Griess 
assay (n=5). 
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Effects of SH-GQDs on hUVECs against oxLDL 
oxLDL-induced impaired vasorelaxation increased the risk of coronary artery 
disease and plaque progression (Byfield et al. 2006; Valente et al. 2014). To monitor 
permeability induced by oxLDL treatment, the transendothelial electrical resistance 
(TEER) across the endothelial layer seeded on transwell plate was measured at different 
time intervals (1, 3, 6, 10 and 24 hr) (Figure 57). hUVECs cultured on transwell inserts 
produced a well-defined endothelial monolayer with a TEER (100 Ω-cm2). When media 
with oxLDL (10 µg/ml) were added into the insert wells, disrupted adherence junctions 
was observed (oxLDL: 67.2±2.2 Ω-cm2 for 24 hr). SH-GQDs (10 µg/ml) showed an 
improvement in TEER (SH-GQDs: 114.6±8.5 Ω-cm2 for 24 hr), indicating that adherence 
junctions were protected by SH-GQDs during the incubation. However, GQDs showed a 
significant reduction in TEER, resulting in an increase in permeability (GQDs: 67.9±8.1 
Ω-cm2 for 24 hr p<0.01, n=3). An increase in permeability could lead translocation of 
lipids across the permeable endothelium which can be improved by SH-GQDs treatment, 
whereas GQDs can’t be utilized for protecting endothelium against oxLDL.  
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Figure 57. Variation of TEER values in response to oxLDL, oxLDL+GQDs and 
oxLDL+SH-GQDs on Raw264.7 cells (** indicates statistically significant difference 
between groups, n=3, p<0.01). 
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Nitric Oxide Release from hUVECs upon VEGF Stimulation  
Nitric oxide (NO) has been identified to play a crucial role in maintaining 
vasodilator tone of endothelium (Sandoo et al. 2010; Oh and Lee 2013a; Oh and Lee 
2014). In addition to vasodilation, platelet adhesion and leukocyte activation can be 
inhibited by NO (McHugh and Cheek 1998).  
NO release from hUVECs mediated by VEGF was examined using Griess assay 
after the incubation of cells for 24 and 48 hr (Bussolati et al. 2001) (Figure 58). It was 
found that NO production in presence of VEGF occurred in a time-dependent manner 
(For 24 hr, 0.4±0.1 µM; 48 hr, 1.7±0.7 µM). NO production was substantially blocked as 
hUVECs were treated with nitric oxide synthase (NOS) inhibitor, L-NAME (L-NAME: 
For 24 hr, 0.13±0.13 µM; 48 hr, 0.8±0.3 µM). As cells were stimulated by VEGF, it 
started to generate NO via NOS. However, hUVECs treated with oxLDL showed no 
detectable concentration of NO as compared to negative control (oxLDL: For 24 hr, 
0.43±0.13 µM; 48 hr, 0.7±0.4 µM). Co-incubation with SH-GQDs showed an increase in 
NO production, which was similar to negative control (10 µg/ml SH-GQDs for 48 hr, 
1.87±0.31 µM).  
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Figure 58. Assessment of nitric oxide (NO) release from hUVECs using Griess assay 
(n=5).  
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in vivo Scavenging Efficacy of SH-GQDs on Zebrafish Larvae by Hydrogen Peroxide 
As shown in Figure 59, the embryonic periods (2 and 48 hour-post fertilization 
(hpf)) were chosen to study the possibility of cytotoxicity of SH-GQDs at varying 
concentration. An exposure of cells to SH-GQDs (1 mg/ml) enhanced mortality, whereas 
it did not exert any harmful effects on embryos at a low dose (0.1 mg/ml).  
To investigate the accumulation profiles of ROS in zebrafish larvae against H2O2, 
larvae stained with ROS-sensitive dye (DCFDA) were utilized (Figure 60). SH-GQDs-
treated larvae displayed lowered fluorescence intensity, indicating a protective role of 
SH-GQDs against oxidative stress. In addition, as the concentration of SH-GQDs 
increased, the fluorescence intensities decreased, and were close to negative control. 
These results indicate that the increased ROS levels caused by oxidative stress (i.e. H2O2) 
were mostly alleviated by the addition of SH-GQDs.  
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Figure 59. Photographs of zebrafish embryos exposed to SH-GQDs (0.1 and 1 mg/ml). 
hpf indicates hour-post fertilization.  
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Figure 60. Quantitative measurements of DCF fluorescence using multimode detector 
(Ex: 485 nm; Em: 515 nm). Embryos were treated with H2O2 (50 µM) in presence of 
varying concentration of SH-GQDs (0, 25, 100, 200 and 300 µg/ml) (n=3).  
 
  
0 
2 
4 
6 
8 
10 
12 
0 30 60 90 120 150 
D
C
F 
Incubation time (min) 
Positive 
25 
100 
200 
300 
Negative 
µg/ml 
µg/ml 
µg/ml 
µg/ml 
H2O2 (50 µM)  
	 145 
in vivo Malformation Caused by SH-GQDs 
Developmental toxicity in zebrafish embryos after the treatment of nanomaterials, 
such as buckminsterfullerene, silica nanoparticles and upconversion nanoparticles, were 
extensively studied (Zhu et al. 2007; Duan et al. 2013a; Wang et al. 2013). Because the 
heart development is a first step during the development process of embryos, zebrafish 
embryos has been used as a predictive model for toxicity studies on heart development 
(Duan et al. 2013a; Bakkers 2011; Duan et al. 2013b; Lin, Zhao, and Nel 2013).  
To assess the in vivo toxicity of SH-GQDs on cardiovascular system, several 
types of malformation at segmentation, hatching and fully developed larvae were 
examined. An exposure to SH-GQDs resulted in malformation in zebrafish embryos 
including head malformation, vent tail, pericardial edema and yolksac edema (Figure 61). 
The results indicated that several malformations including head, vent tail, pericardial 
edema and yolksac edema upon exposure to varying concentrations of SH-GQDs were 
occurred. The pericardial edema and yolk sac edema were found in zebrafish embryos 
treated with 0.1 mg/ml SH-GQDs or greater concentrations. In addition, head 
malformation and vent tail occurred upon being treated with greater than 0.8 mg/ml SH-
GQDs. Previous study indicated that silica nanoparticles may exert a toxic effect, causing 
serious yolk sac and pericardial edema (100 µg/ml or higher) (Duan et al. 2013a). 
Therefore, it was concluded that various type and size materials, such as graphene 
quantum dots and silica nanoparticles, trigger varying degree of malformation at tested 
concentration ranges.  
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Figure 61. Malformation of zebrafish embryos exposed to SH-GQDs (n=20).  
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in vivo Survival Analysis of Zebrafish Larvae against SH-GQDs 
The survival rate of zebrafish larvae against SH-GQDs is a hallmark of 
identifying a potential cytotoxicity. When zebrafish were incubated with varying 
concentrations of SH-GQDs, all or greater than 90% survival embryos were observed in 
negative and treatment group with the concentrations up to 1 mg/ml during first 1 days-
post fertilization (dpf) tested (Figure 62). However, the embryos exposed to higher 
concentrations of SH-GQDs (0.8 or 1 mg/ml) showed a greater mortality at 7 dpf, 
indicative of the dose-dependent mortality at this period of incubation (60% for 0.8 
mg/ml and 46% for 1 mg/ml). Additionally, SH-GQDs at varying concentrations did not 
affect the hatching success rate.  
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Figure 62. Survival analysis of varying concentrations of SH-GQDs (n=30).  
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5.4. Conclusion 
Thiolated-graphene quantum dots (SH-GQDs) were explored as a theranostic 
nanocarrier for endogenous/exogenous compounds against atherosclerosis. SH-GQDs 
prepared by hydrothermal pyrolysis can be utilized to label single-cell biophysics in the 
absence of any extra fluorescence dyes. The efflux of oxLDL from lipid-laden 
macrophages (Raw264.7) was prompted by SH-GQDs treatment. Disrupted adherence 
junction of endothelial cells (hUVECs) by oxLDL treatment was observed, whereas cell 
junctions were protected by SH-GQDs in the presence of oxLDL during the incubation. 
hUVECs exposed to oxLDL in the treatment process of VEGF had no traceable NO. SH-
GQDs played a positive role in the production of NO from hUVECs against oxLDL 
stimulation. The ROS levels triggered by oxidative stress (H2O2) on in vivo zebrafish 
larvae were substantially alleviated by SH-GQDs. The enhancement of in vitro lipid 
efflux in macrophages by SH-GQDs and the scavenging efficacy of SH-GQDs against 
ROS supported its promising usage as a theranostic carrier to prevent foam cell formation 
and subsequent atherosclerotic plaque progression.  
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CHAPTER 6 
SUMMARY AND RECOMMENDATIONS 
This dissertation provides a theoretical basis for understanding pathophysiology 
of atherosclerosis and the role of macrophages in the progress of atherosclerosis. 
Accordingly, we have developed advanced nanographene carriers and evaluated their 
efficacy and cardiotoxicity in vitro cell lines and in vivo using zebrafish embryo model.  
The role of macrophages is integral to understand the cause of progress of 
atherosclerosis plaque. Macrophage is an inflammatory cell with two different subtypes, 
such as M1 and M2 phenotype macrophages. It has been considered as a major cell that 
contributes to the development of atherosclerotic plaque. Although numerous efforts have 
been introduced to alleviate the progression of plaque, only available option is stent 
angioplasty. Despite promising outcomes of using stent angioplasty from clinical trials, it 
poses a major challenge in complete curing the cause of atherosclerosis. The ideal 
treatment strategy for atherosclerosis is to understand the role of macrophages including 
its subtypes (i.e. M1 and M2) and to efficiently target macrophages.  
Recent advances in the field of carbon-based nanomaterial have led to the 
invention of theranostic nanocarriers (therapeutic with diagnostic). Among various 
carbon-based nanocarriers including C60 fullerene, carbon nanotube (CNT) and 
graphene, graphene has drawn a high level of interest in biomedical research. It presents 
versatile mechanical capability, versatility for modification and optical property. Owing 
to their unique properties, graphene and its derivatives, such as graphene oxide (GO), 
reduced-GO (rGO) and ligand-conjugated rGO, have attracted intensive interest from the 
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biomedicine field. Functionalized-rGO offers targeted delivery with photothermal 
ablation of specific cells.  
A novel image-guided delivery system based on thiol-functionalized graphene 
quantum dots (SH-GQDs) was developed for the specific targeting of macrophage 
scavenger receptors (MSR-A or CD204) in the atherosclerosis plague. SH-GQDs have 
optical molecular imaging property, good resistance to photo-bleaching, stable emission 
and easy modulation properties, and are capable of conducting universal ligand–receptor 
recognition and targeted delivery, and displaying superb biocompatibility at the cellular 
level. 
SH-GQDs which did not induce pro-apoptotic stress in Raw264.7 cells and 
zebrafish models highlight the understanding of negligible side effects from SH-GQDs 
and the potential safety for their future applications of SH-GQDs as compared with bare 
core GQDs, guaranteeing that SH-GQDs can serve as a nontoxic fluorescent probe for 
future scientific and clinical usage.  SH-GQD developed as a novel image-guided 
delivery system could provide new insights into the analysis of the universal ligand–
receptor recognition and targeted drug delivery.   
For the future work, it would generate beneficial consequence if SH-GQDs more 
distinctively visualize the plaque lesion using specific peptide moiety (i.e. matrix 
metalloproteinase-2 or -9, MMP-2 or -9) (Figure 63). In addition, the enhanced 
circulation property using PEG brush could be investigated to improve its targeting 
efficacy.   
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Figure 63. Schematic representation of possible functionalization strategies to enhance 
the targetability and circulation with less systemic toxicity.   
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